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Dysregulated trophoblast-specific gene expression mediated by retroviral regulatory 
sequences contributes to preeclampsia (PE) 
Preeclampsia (PE) is a complication that occurs during pregnancy and affects almost 2-8% of 
all pregnancies and is often regarded as a human-specific disorder.1,2 PE is one of the major 
causes of maternal and fetal death.1 Failure of the trophoblast cells to invade into the maternal 
decidua results in the improper remodeling of spiral arteries leading to PE pathogenesis 
(Figure 1).3 Clinically, it is diagnosed as a maternal syndrome, diagnosed by the new-onset of 
hypertension and proteinuria or other end-organ dysfunction after the 20th week of pregnancy. 
So far, the only effective treatment of the disorder is the removal of the placenta tissue and 
delivery of the infant.4  
PE is a disorder of defective placentation and various factors (genetic and epigenetic) have 
been implicated in the abnormal placental development. Epigenetic modifications, such as 
low DNA methylation, as observed in the human placenta tissue increases the expression of 
human endogenous retroviruses (ERVs) essential for the placenta development.5,6 Syncytin-1 
(ERVWE1) derived from a human endogenous retrovirus HERV-W has an essential role in 
human placenta function and development including trophoblast syncytial formation and 
immunosuppression.7,8 Low expression of Syncytin-1 due to hypermethylation in PE 
placentas has been detected.9 There are several other examples of genes that are particularly 
expressed in the human placenta tissue due to the co-option of solitary endogenous retroviral 
(ERV) LTRs (Long terminal repeats) into the regulatory region that drive their placenta-
specific gene regulation, either by contributing a unique enhancer or an alternative 
promoter.10 
The aim of this study is to identify additional genes that are regulated by the human ERV-
LTRs in the human placenta specifically, and are dysregulated in PE. To achieve this aim, the 
transcriptome of primary human trophoblast cells of 5 healthy and 5 early-onset PE placentas 
were analyzed by RNA sequencing (RNA-seq). RNA-seq analysis identified genes (n=335) 
with stronger expression in the trophoblast cells as compared to other human body tissues. 
Additionally, some of the genes (n=88) showed co-regulation of expression by the human 
ERV-LTRs in their vicinity (10-kb upstream of transcription start side (TSS) of the gene). 
Since my interest was to identify the new targets of PE pathogenesis, so I focused on genes 




Quantitative polymerase chain reaction (q-PCR) was performed on human PE placenta 
samples of Oslo-cohort-II to confirm the dysregulation of genes. CYP11A1, EPS8L1, 
CSF2RB, SPINT1, ALDH3B2 and DACT2 were identified to be significantly dysregulated in 
early-onset PE patients (Oslo-cohort-II). GFP-reporter assay confirmed the enhancer activity 
of the ERV-LTRs associated with the six candidate genes. To gain deeper insight into the 
functional analysis of the genes in PE pathogenesis, I focused on EPS8L1. EPS8L1 is an 
epidermal growth factor receptor pathway substrate 8-related protein 1. I found it to be 
significantly upregulated in PE patients of Oslo-cohort-II, both at the level of mRNA and 
protein. The upregulation at the mRNA level was also seen in PE patients of Charite and Kiel 
cohort. Moreover, I also detected the EPS8L1 upregulation in the serum of PE patient of a 
high-risk pregnancy cohort from Manchester. These analyses made EPS8L1 a strong 
candidate to study further the function of this protein in PE pathogenesis. EPS8L1 expression 
was found to be consistent through-out pregnancy, by analyzing samples from early gestation 
(n=92) and at term (n=49) of pregnant women of Graz cohort. The analysis confirmed that the 
upregulation of EPS8L1 is PE specific and not related to the gestational-age changes.  
To gain insight in the function, I established an in-vitro EPS8L1 overexpressing trophoblast 
cell line by using Sleeping Beauty (SB) transposon system to mimic the in-vivo conditions of 
EPS8L1 overexpression in PE patients. Global transcriptome changes by EPS8L1 
overexpression were analyzed by RNA sequencing. The differential gene expression analysis 
revealed dysregulation of important pathways involved in trophoblast function like invasion, 
proliferation, angiogenesis and maintenance of cell redox homeostasis upon overexpression of 
EPS8L1. Mass spectrometry analysis further confirmed that EPS8L1 interacts with different 
proteins involved in pathways that are important for placental development.  
This study identified a new gene EPS8L1, regulated by primate-specific ERV-LTR in 
trophoblast cells that has a predominant role in the human placenta development and 
demonstrated that its dysregulation affected multiple pathways involved in trophoblast 
function like invasion, angiogenesis and maintenance of cell redox homeostasis. Furthermore, 
this study leads to the better understanding of the disease by explaining certain aspects of 
human-specific nature of PE. 
Keywords: Preeclampsia (PE), Transposable elements (TEs), Endogenous Retroviruses 







Eine dysregulierte Trophoblasten-spezifische Genexpression, die durch retrovirale 
regulatorische Sequenzen vermittelt wird, trägt zur Präeklampsie (PE) bei. 
Präeklampsie (PE) ist eine Komplikation, die während der Schwangerschaft auftritt, fast 2-8% 
aller Schwangerschaften betrifft und human spezifisch ist.1,2 PE ist eine der Hauptursachen 
für den Tod von Mutter und Kind.1 Eine abnormale Plazentaentwicklung aufgrund einer 
verminderten Trophoblasteninvasion und einem gestörten Umbau der Spiralarterien trägt zur 
Pathogenese der PE bei (Figure 1).3 Klinisch wird die PE durch Bluthochdruck und 
Proteinurie, auftretendnach der 20. Schwangerschaftswoche, diagnostiziert und kann durch  
eine Funktionsstörung von Organen begleitet werden. Bei besonders schweren Verläufen ist 
die frühzeitige Endbindung die letzte Möglichkeit das Überleben der Mutter zu 
gewährleisten.4  
PE basiert auf einer gestörten Plazentation und eine Vielzahl an genetischen, sowie 
epigenetischen Faktoren wurde für eine abnormale Plazentaentwicklung beschrieben. 
Epigenetische Modifikationen, wie die DNA-Hypomethylierung verstärken die Expression 
von endogenen Retrovirus (ERVs) im menschlichen Plazentagewebe.5,6 Syncytin-1 
(ERVWE1), das aus einem humanen endogenen Retrovirus HERV-W stammt, spielt durch 
die Bildung von Trophoblasten-Syncytien und der Immunsuppression eine wichtige Rolle bei 
der Entwicklung und Funktion der menschlichen Plazenta.7,8 Eine verminderte Expression 
von Syncytin-1 wird durch Hypermethylierung in der PE-Plazenta verursacht.9 Weitere Gene 
werden aufgrund von co-optionen solitärer Retrovirus-LTRs in deren regulatorischen 
Regionen human spezifisch im Plazentagewebe exprimiert. Dies geschieht entweder durch die 
Bereitstellung eines neuen Enhancers oder eines alternativen Promotors.10  
Das Ziel dieser Studie ist es, weitere Gene zu identifizieren, die durch ERVs in der 
menschlichen Plazenta spezifisch reguliert werden und in PE dysreguliert sind. Um dieses 
Ziel zu erreichen, wurde das Transkriptom von primären menschlichen Trophoblastenzellen 
von 5 gesunden und 5 früh einsetzenden PE-Plazenten mittels RNA-Sequenzierung analysiert. 
Es wurden 335 Gene identifiziert, welche eine höhere Expression in den Trophoblastenzellen 
im Vergleich zu anderen Geweben aufwiesen. Zusätzlich zeigten einige der Gene (n=88) eine 
Co-Regulation der Expression durch retrovirale LTRs (10-kb  5‘ des transcription start side 
(TSS) des Gens). Hauptinteresse lag hierbei auf den Genen, welche ebenfalls eine 




Quantitative Polymerasekettenreaktion (q-PCR) wurde an humanen PE-Plazentaproben der 
Oslo-Kohorte durchgeführt, um die Dysregulation von Genen zu bestätigen. Es wurde 
festgestellt, dass die Gene CYP11A1, EPS8L1, CSF2RB, SPINT1, ALDH3B2 und DACT2 bei 
Frauen mit früh einsetzender PE signifikant dysreguliert sind. Ein GFP-Reporter-Assay 
bestätigte die Enhancer-Aktivität von 6 Genen welche assoziiert waren mit Retrovirus-LTRs. 
Im folgenden konzentrierte ich mich auf das Gen EPS8L1 (Epidermal growth factor receptor 
kinase substrate 8-like protein 1). Seine Funktion ist nicht bekannt. Ich konnte zeigen, dass es 
in Plazenta Proben von Frauen mit PE sowohl auf mRNA-, als auch auf Proteinebene 
signifikant hochreguliert ist. Diese Hochregulation wurde in zwei weiteren Kohorten 
verifiziert. Darüber hinaus konnte ich auch eine Hochregulation von EPS8L1 im Serum von 
Frauen mit PE detektieren. Die EPS8L1-Expression erwies sich während der gesamten 
Schwangerschaft als konsistent, wie anhand von Plazenten aus der frühen Schwangerschaft (n 
= 92) gezeigt werden konnte. Die Analyse bestätigte, dass die Hochregulation von EPS8L1 
PE-spezifisch ist und nicht mit den Veränderungen des Gestationsalters zusammenhängt. 
Eine EPS8L1-überexprimierende Trophoblasten-Zelllinie wurde mittels des Sleeping Beauty 
(SB) -Transposonsystem etabliert. Die globalen Transkriptomveränderungen durch die 
EPS8L1-Überexpression wurden mittels RNA-Sequenzierung analysiert und ergab eine 
Dysregulation wichtiger Signalwegen, wie Invasion, Proliferation, Angiogenese und 
Aufrechterhaltung der Zellredoxhomöostase. Eine Massenspektrometrie-Analyse bestätigte 
ferner, dass EPS8L1 mit verschiedenen Proteinen interagiert, welche für die 
Plazentaentwicklung wichtig sind. 
Diese Studie identifizierte EPS8L1, das durch primaten-spezifisches ERV-LTR (MLT1G1) in 
Trophoblastenzellen reguliert wird, als einen wichtigen Faktor in der Entwicklung der 
menschlichen Plazenta. EPS8L1 ist in der PE Plazenta dysreguliert und involviert in mehrere 
Signalwege und die Funktionalität von Trophoblasten wie Invasion, Angiogenese und 
Redoxhomöostase. Hierdurch führt diese Arbeit zu einem besseren Verständnis der PE und 
deren human-spezifischer Natur.




1. Background and Introduction 
1.1. Preeclampsia (PE) 
Preeclampsia (PE) is one of the obstetrical complications characterized as the new emergence 
of hypertension (>140/90 mmHg) that develops during the second half of gestation, followed 
by excessive proteins in the urine (>300 mg/l protein in a 24 hr urine collection) or any of the 
features of end-organ injury, including low blood platelet count (<100,000), compromised 
liver function, kidney failure (increased serum creatinine >1.1 mg/dL), excessive fluid in the 
lungs or the start of cerebral or visual disturbances.11 PE is one of the foremost cause of 
maternofetal mortality and morbidity.1 Placenta tissue is the primary source of PE 
development.12 The symptoms disappear when the placenta is delivered. Defects in the deep 
invasion of the trophoblasts into the maternal blood vessels is the key factor in PE 
development (Figure 1). The existence of PE has only been observed in humans and not in 
other mammals or non-human primates.2 To understand the pathophysiology of PE, it is 
important to know the normal/ healthy placenta development and the cell composition of the 
placenta tissue, which is explained further in detail.  
 
Figure 1. Non-transformed spiral arteries in PE pregnancy 
In PE placentas, Extravillous trophoblasts (EVTs) fail to invade and transform the myometrial 
segment of the spiral arteries, resulting in narrow arteries and decreased utero-placental blood 
flow. In contrast, in a healthy placenta, the trophoblasts increase the vasculature of spiral 
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arteries by invading into the one-third of the myometrium, resulting in proper placental 
perfusion. Adapted from13 
1.2. Healthy pregnancy 
 
Pregnancy is the time from fertilization to child birth, lasting for about 38 weeks in humans.14 
The time span of the pregnancy varies between different species. A healthy placenta is a pre-
requisite for a healthy pregnancy outcome. Placenta functions as an essential feto-maternal 
unit and controls the growth and development of the fetus. Placentas are quite diverse among 
mammals based on their morphology, cell type and endocrine function. For example the 
placentas of humans, rodents, and ruminants (sheep and cattle) are all very different. Humans 
have hemochorial placentation; the fetal trophoblasts are in contact with the maternal blood 
similar to the mouse/rat placenta but it is highly invasive.15 The human placenta when 
delivered has a disc-like shape and a weight of about 470 grams. It normally has a diameter of 
22 cm and a central thickness of around 2–2.5 cm. The fetus is connected with the placenta by 
an umbilical cord of around 55–60 cm in length, which has two arteries and a vein.16 A 
healthy placenta expresses around 70% of the total protein coding genes in human cells.17 
Some of these genes have higher expression (350 genes) and a few (100 genes) were 
exclusively detected in the human placenta tissue. Placenta-specific genes are implicated in 
the human placenta evolution and sustenance of pregnancy. Abnormal development of 
placenta is the predominant feature of major disorders of pregnancy such as preeclampsia 
(PE), intrauterine growth restriction (IUGR), recurrent miscarriage and preterm birth (PTB).18 
1.2.1. Placenta development in a healthy pregnancy  
After fertilization (6-10 days), the blastocyst, also known as pre-implantation embryo, 
attaches to the maternal endometrium, initiating the process of placentation. This phase of 
placental development is called as prelacunar.19 The pre-implantation embryo consists of an 
inner cell mass (ICM) that is surrounded by the trophectoderm layer. The embryo and the 
umbilical cord are generated from the ICM and the trophectoderm leads to the establishment 
of the fetal membranes and the placenta tissue. Following implantation, the trophoblast cells 
in the trophectoderm layer differentiates into syncytiotrophoblasts, that invades through the 
surface epithelium and transforms the  endometrium into decidua.20 Fluid filled spaces also 
known as Lacunae appear, after 8 days of conception, within the syncytiotrophoblasts layer. 
The cells around the lacunae (trabeculae) infiltrate into the wall of the decidua leading to the 
establishment of villous trees of the placenta tissue.21  This is called the lacunar stage. 
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The cytotrophoblast cells underlying the syncytiotrophoblasts, after 12 days of conception, 
proliferate exponentially to form the projections in the primary syncytium ultimately 
establishing the direct contact with the maternal tissue and transforming the projections into 
primary villi. Soon after the day 17th, mesenchymal cells follow the cytotrophoblast and 
penetrate into trabeculae to form secondary villi. Trophoblastic cell columns (CCC) filled 
with cytotrophoblast are established at the end of trabeculae and the mesodermal cells are 
unable to reach the maternal side of the trabeculae. First fetal capillaries appear; after 18 days 
of fertilization that converts the corresponding villi into tertiary villi. The villous tree grows 
rapidly all through the gestation but the proportion of newly established primary and 
secondary villi structures in a placenta at term is lower as compared to the fully functional 
tertiary villi. Cytotrophoblast cells of the cell column (CCC) located at the decidua-placenta 
interface invades into decidua as extra villous trophoblasts (EVTs). The maternal blood is 
supplied to the developing placenta until the 12th week of pregnancy and the placenta tissue 
continues to grow throughout the gestation. 
 
Figure 2. First trimester villi in a healthy pregnancy 
Human placental villi attached to the maternal decidua and the major trophoblast subtypes are 
shown. Extravillous trophoblasts (EVT) including endovascular and interstitial EVTs, 
syncytiotrophoblasts (SCT) and villous cytotrophoblast (VCT) are shown. Adapted from22 
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1.2.2. Placenta tissue composition 
 
The placenta is a heterogeneous tissue comprising of numerous cell types that are involved in 
highly diversified functions ranging from adhesion, migration, invasion, remodeling of blood 
vessels, production of pregnancy associated hormones, metabolism and interchange of gases 
and nutrients between the mother and the baby.23 The functional unit of human placenta is the 
trophoblast. In 1889, the word ‘trophoblast’ was first termed by Ambrosius Arnold Willem 
Hubrecht. He described them as cells that are involved in the transportation of the nutrients 
and maintain a protective shield between the mother and the developing embryo.24 
Trophoblast cells are further divided into three different subtypes: these include the 
syncytiotrophoblast (SCT), the villous cytotrophoblast (VCT) and the extravillous trophoblast 
(EVT) (Figure 2). 
1.2.2.1. Syncytiotrophoblast (SCT) 
 
Syncytiotrophoblasts (SCTs) are the cells that form the outer lining of the placental villi and 
are in close proximity with the maternal blood and the uterine gland (Figure 2). SCTs have 
more than one nucleus and are terminally differentiated. All the gaseous and nutrient 
interchange between the mother and the fetus is carried out by these cells. The SCTs have an 
endocrine function, they secrete hormones and proteins into the maternal circulation that are 
crucial for the maintenance of a healthy pregnancy. Moreover, they also act as an 
immunological shield and protect the allogeneic fetus from the response generated by 
maternal immune system. Since SCTs does not express any human leukocyte antigen (HLA) 
molecules, they escape the response from maternal immune cells.20,25  
1.2.2.2. Villous cytotrophoblast (VCT) 
 
The cells directly underneath the multinucleated syncytial layer are the mononucleated villous 
cytotrophoblast (VCT) (Figure 2). Due to their extremely proliferative and mitotic capacity, 
they are considered as trophoblast stem cells.26 VCT differentiate into either fusion lineage 
and lead to SCT formation or they differentiate into invasive interstitial cytotrophoblast 
cells.27 As pregnancy progresses, the number of VCT declines and at the time of delivery they 
are only about 25% of the entire amount of the VCT in the placenta tissue. 
1.2.2.3. Extravillous trophoblast (EVT) 
 
The extravillous trophoblasts (EVT) are derived from the cytotrophoblast cell columns 
(CCCs) located at the ends of the anchoring villi (AVs). The invasive EVTs are additionally 
divided into interstitial, endovascular and endoglandular EVTs based on their invasion in 
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either into the maternal decidua or the glands of the uterus. The interstitial trophoblasts 
(iEVT) drift through the maternal uterine stroma in the direction of spiral arteries and veins 
and invade more than half of the myometrium.28 The endovascular trophoblast (eEVT) moves 
internally in the arteries and replaces the native endothelial and smooth muscle cells to 
establish the trophoblast plugs.28,29,30 Trophoblast plugs then block the maternal blood 
entering in the spaces of the villi of placenta until the time point where proper circulation 
(haemochorial placentation) is established, which is usually towards the end of the first 
trimester.31,32,33 This trophoblast mediated conversion of highly resistant vessel into a low 
resistant is an essential adaptation for proper fetal perfusion and a healthy pregnancy.34 
Endoglandular trophoblasts invade specifically into the maternal glands of the uterus and 
restore the epithelium of the glands to establish the histotrophic nutrition for the fetus under 
developement.35,36 The process of invasion is at peak during the end of 12th week of 
pregnancy.37 In pregnancies affected by PE, the maternal blood vessels are not sufficiently 
transformed due to the shallow invasion of the endovascular trophoblasts (eEVT) leading to 
abnormal placenta development and decreased blood flow between the mother and the fetus 
(Figure 1). Therefore, the significance of the role of different types of extra-villous 
trophoblasts (EVTs) in human placenta development during the early stages of pregnancy 
cannot be disregarded. Other than the different types of trophoblast cells, the placenta also 
contains cells that includes fibroblasts, immune (Hofbauer) and vascular cells (Figure 2). 
1.3. Incidence of PE  
 
The incidence of PE varies between different ethnic backgrounds and geographical 
locations.38,39 In under developed countries due to the inadequate facilities for maternal and 
neonatal intensive care, maternal death rate is as high as 15% and the infant mortality rate is 
three times higher as compared to 0% to 1.8% in developed countries.40 PE is one of the most 
common cause of preterm birth (PTB) (15-20%) and fetal growth restriction (FGR) (12-
25%).41,42 
1.4. Classification of PE 
 
Depending upon the gestational age at diagnosis, the disease can be categorized as early-onset 
(< 34 weeks) and late-onset PE (≥ 34 weeks). Early-onset PE is relatively uncommon (12% of 
all PE) contrary to late-onset PE which is 88% of all PE. However, early-onset PE has a 
greater chance of maternal and fetal complexity as compared to late-onset PE. Late-onset PE 
often leads to a syndrome (HELLP) characterized by haemolysis, elevated liver transaminases 
and low platelets, and can also lead to eclampsia and maternal death.43,44  
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1.5. Risk factors of PE 
 
Multiple risk factors have been linked with PE.  Among them, women having a family history 
of PE are at a higher risk of developing PE. Besides this, there are some other known risk 
factors that can contribute to PE. For example women having age <20 or >35 years, having 
pre-gestational diabetes, pre-existing chronic hypertension/ renal disease, previous history of 
intrauterine growth restriction (IUGR), placental abruption or stillbirth, pregnancy with more 
than one baby, increased BMI before pregnancy, antiphospholipid antibody syndrome, 
systemic lupus erythematosus and assisted reproduction technology (ART).45,46  
1.6. Pathophysiology of PE 
 
PE has a complex pathophysiology and is a consequence of disproportion of factors produced 
by the placenta and the maternal adaptation to them. Maternal-fetal genetic incompatibility, 
exposure to paternal antigens and immunological factors lead to improper invasion of the 
trophoblasts resulting in the failure of remodeling of arteries in the myometrium, hence 
causing PE (Figure 3).13 However, still the etiology of PE is not known clearly and it has been 
observed that placental ischemia/ hypoxia is a key factor in the development of this disorder. 
The ischemic placenta under stress, releases inflammatory cytokines, anti-AT1 autoantibodies, 
trophoblast-derived micro particles, angiogenic and antiangiogenic factors into the maternal 
blood, thus generating intravascular inflammatory reaction and resulting in the clinical 
presentation of the disorder (Figure 3).47,48    
Remodeling of the spiral arteries of the uterus supports fetal growth by achieving increase in 
the uterine blood flow during the development of placenta. The trophoblast cells are the key 
players in this process; they invade the arteries of not only the decidua region, but also of the 
myometrial segment of the spiral arteries. They increase the vasculature of the arteries by 
destroying the arterial media and endothelium. This results in lower resistance in the blood 
vessels and allows proper flow of the blood to the fetus resulting in a healthy pregnancy.49 In 
case of PE (and eclampsia), trophoblast cells fail to migrate and reform the myometrial 
segment of the spiral arteries resulting in defects in placentation and ultimately leading to 
utero-placental ischaemia.50 Since trophoblast cells are responsible for this key developmental 
process, defects in trophoblast could be one of the reasons for the improper placenta 
development as seen in case of PE.  
In a healthy pregnancy at the site of trophoblast invasion, the maternal immune response 
against the paternal antigens of the fetus is not generated, possibly, because of the activity of 
the regulatory T (Treg) cells and the natural killer (uNK) cells in the decidua.51 Uterine 
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natural killer (uNK) cells play a very important role in mediating the process of invasion of 
the trophoblasts during pregnancy. The invading extravillous trophoblasts (EVTs) expresses 
classical class I molecule HLA-C and non-classical HLA-E and HLA-G, that interacts with 
the receptors present on the uterine natural killer (uNK) cells such as CD94/ NKG2, killer-cell 
immunoglobulin-like receptors (KIR) and members of the immunoglobulin-like transcript 
(ILT) family, to mediate the process of trophoblast invasion at the site of implantation.51,52 
Angiogenic factors as well as chemokines are secreted by the uNK cells to facilitate the 
trophoblast invasion. In PE, the interaction between the invading trophoblast cells and the 
uterine NK cells is disturbed leading to intravascular inflammatory response.51,52 
Elevated levels of pro-inflammatory/ Th1 cytokines, for example IL-1, IL-2 and interferon- -γ 
and decreased levels of Th2 cytokines IL-10 and IL-5 have been demonstrated in PE 
pathogenesis.53 Additionally, activation of NF-kappa B, endoplasmic reticulum (ER) and 
oxidative stress in the placenta tissue generates inflammatory response by inducing the 
production of inflammatory cytokines (TNF-alpha, IL-6 and IL-17) resulting in the 
endothelial cell damage, therefore contributing to PE pathology.54 Defective immune 
responses and genetic disposition increases the sensitivity against the effects of angiotensin 
II.55 PE patients have been reported with higher levels of autoantibodies against type-1 
angiotensin II receptor, which are known to activate the angiotension II receptor (AT1) in the 
endothelial cells.56 The anti-AT1 autoantibodies when administered in pregnant rats, induced 
hypertension and proteinuria which is the clinical presentation of PE.57 
Human placental development is very robust. After 21 days of fertilization, a protective shell 
of trophoblast cells encloses the fetus and establishes an interface with the maternal side. This 
phase of fetal development is supported by the secretions from the uterine glands 
(histotrophic nutrition).58 During the early phases of implantation, the proliferation of the 
trophoblast is facilitated by the low oxygen tension in the gestational sac. This condition is 
conducive for trophoblasts to attach the blastocyst to the maternal tissues.59 Lacunae are 
created within the trophoblasts which fuse to establish the intervillous space. A shift from 
histotrophic nutrition to the establishment of haemochorial placentation occurs when spiral 
arteries open at the spaces between the villi. Initial phase of placenta development happens 
under a state of relative hypoxia.60  Oxygen tension is ultimately increased due to the first rush 
of blood into the intervillous space which generates oxidative stress and supports 
differentiation of trophoblasts from a proliferative to an invasive phenotype. This shift of 
trophoblast cells facilitates the deep influx into the decidua resulting in the physiological 
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transformation of the spiral arteries.60 Under hypoxic conditions, the natural process of protein 
folding is interrupted by endoplasmic reticulum, indicated as the unfolded protein response 
(UPR).61 The UPR affects cell proliferation and can undergo apoptosis of the trophoblast 
cells. The apoptosis of the trophoblasts produces micro and nanoparticles that are discharged 
into the maternal circulation, ultimately activating the immune response.62,63 Many studies 
have reported the connection of ER distress and the stimulation of the UPR in PE and 
IUGR.61,64 
Besides ER stress, oxidative stress is also linked with pathogenesis of PE as mentioned 
before. It originates when the generation of reactive oxygen species (ROS) overcomes the 
underlying antioxidant defense systems.65 Excessive release of pro-inflammatory cytokines 
and chemokines have been detected due to the higher oxidative stress.66 In the placentas of PE 
patients, due to the defected spiral arteries remodeling, the oxidative stress is induced because 
of sporadic hypoxia and reoxygenation.65 The strength of uterine ischemia is affected by the 
severity of improper placenta development and requirement of the fetus for blood supply. 
Higher ROS affects protein carboxylation, lipid peroxidation and DNA oxidation as noticed 
before in placentas of PE patients.65 Many studies have indicated that the antioxidant 
processes in placenta tissue are compromised in PE patients as compared with healthy 
controls.67  
For a healthy placentation, the process of angiogenesis is very crucial.68 Improper blood 
vessel development is well known to contribute to the establishment of PE. In PE patients, 
antiangiogenic factors have been detected to have higher expression in contrast to the healthy 
controls, which include soluble vascular endothelial growth factor receptor 1 (VEGFR‑1) and 
soluble endoglin (Figure 3).69 Soluble VEGF receptor binds to the circulating angiogenic 
factors (VEGF and PlGF) in the maternal blood and hinders their biological activity, resulting 
in imperfect angiogeneisis.70 Soluble endoglin affects the migration and proliferation of 
endothelial cells by acting as a co-receptors of transforming growth factor β1 and β3 (TGF‑β1 
and TGF‑β3).71 Defects in the human ENG is known to cause disease of vascular impairment, 
characterized as haemorrhagic telangiectasia.72 In-vitro experiments confirmed that the effect 
of s-endoglin on endothelial tube formation is similar to the sVEGFR‑1.71 The abnormal 
angiogenic and antiangiogenic balance is not limited to PE but has been observed in other 
obstetric disorders like IUGR, PTB, spontaneous abortion and fetal death (Figure 
3).73,74,75,76,77 However the clinical outcome (fetal death, PE with IUGR, IUGR alone and late-
PE) is depended on the maternal response and the severity of the antiangiogenic state. 
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Decreased utero-placental blood flow, hypoxia, oxidative stress, inflammatory cytokines, 
release of trophoblast derived particles, anti-AT1 autoantibodies, intravascular inflammation, 
leukocyte activation and endothelial cell dysfunction results in the imbalance, therefore 
affecting multiple organs resulting in the clinical presentation of PE. 
 
 
Figure 3. Pathophysiology and clinical features of PE 
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Risk factors related to pathogenesis and their contribution in the multiorgan features of PE are 
indicated. (AT1: anti‐angiotensin II type I receptor antibodies, ER: endoplasmic reticulum, 
ICH: intracerebral haemorrhage, IUGR: intrauterine growth restriction, PlGF: placental 
growth factor, ROS: reactive oxygen species, VEGF: vascular endothelial growth factor and 
sVEGFR-1, soluble vascular endothelial growth factor receptor 1). Adapted from 13 
1.7. Epigenetics and PE  
 
DNA methylation and histone modifications are two well studied epigenetic modifications 
that are known to regulate the expression of the genes without altering DNA sequences 
(Figure 4).78 Epigenetics has been recognized as an important mechanism, it plays a vital role 
in human placenta development and alterations in epigenetic mechanisms have been 
implicated in PE pathogenesis.79 DNA methylation regulates various other biological 
mechanisms, together with lineage specification, inactivation of chromosome X, imprinted 
genes, stability of genome and control of the retrotransposon activation.78 In human placenta, 
the transcription of various genes is influenced by changes in the DNA methylation due to 
external factors including exposure to toxic chemicals (smoking), nutrition, psychological 
state and assisted reproductive treatments.80,81  
Mammalian placentas have unique epigenetic profile due to the less DNA methylation as 
compared to somatic tissues. Human placenta has 14–25% lower amount of global CpG DNA 
methylation.82-85 Epigenetic modifications related to placenta has been speculated to support 
unique functions of placenta 5,6 and alterations in DNA methylation process can result in 
abnormal placental morphology and outcomes of pregnancy.86 Decreased expression of 
Syncytin-1 due to increased DNA methylation has been observed in PE patients.9 Syncytin-1 
has a vital role in human placental evolution, growth and for a successful pregnancy. 7,8  
Non-imprinted genes were found to be affected by the epigenetic alterations, such as 
SERPINB. Higher expression of SERPINB was detected in PE placentas due to low promoter 
CpG methylation.87 Similarly, impaired DNA methylation in the promoter regions of 
Vascular Endothelial Growth Factor A (VEGF), Vascular Endothelial Growth Factor 
Receptor 1 and 2 (FLT-1 and KDR) in PE patients were also identified.88,89,90 However, it is 
not understandable yet that whether the observed differences are the effect or the reason 
behind the development of PE.  




Figure 4. Epigenetic mechanisms of gene regulation 
A) Histone modifications such as acetylation (Ac), phosphorylation (Ph) and methylation 
(Me) are shown. B) DNA methylation is carried out by DNA methyltransferase enzymes 
(DNMTs) that are involved in adding the methyl group at cytosine base of CpG sites, 
therefore, repressing the gene expression as well as the activity of TEs in the genome. C) 
Non-coding RNA (ncRNA) such as microRNAs (miRNA) regulates the protein translation by 
blocking the transcribed mRNAs. Adapted from78 
1.8. Epigenetics and activation of transposable elements (TEs) 
 
In mammals including humans, TEs are globally methylated in the somatic tissues and 
therefore are not able to be transcriptionally active.91,92,93 In placenta tissue, DNA methylation 
is very low in certain regions due to which TEs, especially, endogenous retroviral (ERV) 
derived sequences such as ERV-LTRs are exponentially expressed as compared to other 
human tissues.82,83,84,85,94,5,6,10 In human placenta, LTRs derived from HERV-E, function as 
alternative promoter of many cellular genes and it was found to be less methylated as 
compared to the blood cells where they do not exhibit the promoter activity.5,38  
Correspondingly, another type of transposable elements, LINE1 elements (non-LTR 
retrotransposons), showed lower (almost 43%) DNA methylation in placenta as compared to 
the blood cells.95 Placenta-specific DNA methylation changes were identified to be linked 
with the regulation of the expression of Syncytin-1 throughout pregnancy.6,96 It is 
exponentially expressed at the beginning of placentation, to mediate the cell-cell fusion 
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activity and the expression declines at term, when the cell fusion activity is no longer 
required. Expression of some of the essential placenta-specific genes (INSL4, EDNRB, PTN, 
MID1 and IL2RB) derived from human endogenous retroviral  sequences (ERV-LTRs) is also 
a consequence of low methylation in the human placenta.10,6 The function of ERV-LTRs in 
driving the placenta-specific gene expression is explained later in detail. 
1.9. Transposable elements (TEs) 
 
Almost half or more of the human DNA is composed of TEs and during primate evolution 
TEs have been co-opted to carry out a predominant role in rewiring the human genome.97 TEs 
were found in late 1940s by Barbara McClintock in maize and she introduced them as 
“controlling elements”.98 Originally, TEs were considered junk DNA for a very long time but 
after that many studies have reported that almost 20% of the conserved DNA regulatory 
regions such as promoters, enhancers and transcription factor binding sites are derived from 
TEs.99,100,101,102,103 Normally, their transcriptional ability is repressed in the cells, but their co-
option has been demonstrated to mediate events such as recombination, splicing, 
exonification, and diverse means of gene regulation.104  
1.10. Tissue-specific regulation by TEs 
 
TEs are known to contribute to the tissue and lineage specific effects besides their critical role 
in regulation of adjacent genes, splicing and exonification.104 They have several 
characteristics that impart the tissue-specific effect. 
1. They provide specific transcription factor binding sites due to which the expression is 
confined to a particular tissue.105 ,99  
2. They have the ability to reproduce inside the genome and regulate multiple genes.  
3. They expand the possibility of distinct lineage variability because their effect is 
limited to the genomes they have infected.  
Distinct tissue and developmental phase specific consequences have been predominantly 
disclosed in cancers, where specific TEs are often detected to be expressed 
tremendously.106,107,108,109,110,111,112 Orthologous genes are regulated in homologous tissues 
(Prolactin (PRL gene)) due to various autonomous co-options of distinct TEs across 
species.113 The envelope gene of different endoviruses (Syncytin gene) has been recruited to 
perform the similar activity in the placenta tissue of different lineages.114-116,117 TEs are 
known to rewire the transcriptional control of gene expression in a contextual manner.  
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1.11. Types of TEs 
 
TEs are divided into two important classes  
1. Retrotransposons: that mainly function through reverse transcription. 
2. DNA transposons: code their own transposase that mediate their insertion and excision. 
However, in the human genome only retrotransposons are active and have played an 
important role in the genomic evolution.118,119  
1.11.1. Retrotransposons 
 
Almost half (42%) of the human genome consists of retrotransposons, while DNA 
transposons are less than 3%.120 Retrotransposons have the ability to initially transcribe into 
an RNA, and then convert back into similar DNA sequences by reverse transcription. They 
can amplify easily by a "copy-and-paste" system, due to which they exist all over in the 
eukaryotic genomes. Based on the presence or non-existence of long terminal repeats (LTRs), 
type of open reading frames (ORF), coding sequences and duplication of target sites, 
retrotransposons are further divided into two classes,  
1. LTR-retrotransposons (LTR: long terminal repeats) and 
2. Non-LTR retrotransposons (long interspersed elements (LINEs) and short interspersed 
elements (SINEs) 
1.11.1.1. LTR retrotransposons (Long Terminal Repeat)  
 
Long terminal repeats (LTR) retrotransposons consist of sequences that range in size between 
100 bp to over 5 kb. They are similar to a retrovirus but they have been classified separately. 
LTR endogenous retroviruses (ERVs) evolved from ancient descendants of exogenous 
retrovirus that infected germ line cells and were conserved in the germline. Endogenous 
retroviruses (ERVs) possess three viral genes; group-specific antigen (gag), polymerase (pol) 
and envelope (env) surrounded by two long terminal repeats (LTRs) that contain promoter 
elements, enhancer and polyadenylation sites (Figure 5).121 Transposed LTRs in the human 
genome account for 8% and the mouse genome contains about 10% of the ERV-derived 
sequences.122 Occasionally, due to the genetic rearrangements, solo ERV-LTRs are generated. 
A solo ERV-LTR co-opted near a cellular gene, can augment the transcription from the native 
gene promoter in a tissue-specific way. 
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1.12. Role of LTR retrotransposons in human placenta development 
 
Human placenta development is very unique and novel. Humans have extremely invasive 
placenta as compared to the placentas of mouse and rat.123  The invasive phenotype can be 
attributed to the primitive infection of the retroviruses (ERV) resulting in the expression of 
genes that are precisely elevated in the human placenta and are involved in the process of 
invasion during pregnancy.124 Functional evolution of the human placentation owing to the 
insertion of human endogenous retrovirus (HERV) has been a major event.125,126,127 
Phylogenetic analysis indicated that during primate evolution endogenous retroviruses 
(ERVs) integrated into the vertebrate’s germ cells around 25-45 million years ago after the 
divergence of New and Old World monkeys.124 The higher expression of few HERV families 
was found specifically in the human placenta tissue, that includes human endogenous 
retrovirus K, W, F, R and H (HERV-K, HERV-W, HERV-F, HERV-R and HERV-
H).125,128,126,127,129,130,131 LTRs derived from these ERVs are also highly transcribed in the 
placenta tissue as compared to other body tissues and there are many studies that manifest the 
role of ERV-LTRs in the human placentation (Figure 5).132,124,133,109,134,135,136,137  
Endogenous retroviruses (ERVs) have contributed to the diversification of the human 
placenta and might explain the differences in the species in terms of the gestation, the total 
number of fetuses in one pregnancy, the size of the fetus and the time of the gestation.138 
Certain genes are expressed in the human placenta that are derived from the genes of 
endogenous retroviruses (ERVs). Besides this, there are a few genes that have placenta-
specific enhancers and promoters derived from ERV sequences. All of them are known to 
have essential roles in the human placentation. ERV-derived genes and ERV-derived 
placenta-specific promoters and enhancers that are known so far in the literature are discussed 









Figure 5. Role of endogenous retroviruses (ERVs) in human placenta  
A) Genomic structure of an endogenous retrovirus (ERVs) containing retroviral genes flanked 
by LTRs. B) Examples of  Syncytin 1 as a retroviral derived protein125  and co-option of the 
solo ERV-LTR as an enhancer for CRH 139 in the human placenta. (LTR: long terminal 
repeats). Adapted from140  
1.12.1. Placenta-specific genes derived from endogenous retroviruses (ERVs) 
 
The number of genes confined to the placenta tissue that are not derived from ERVs are 
limited.141 Trophoblast-restricted protein (Tpbp) a and b in mouse142 and the similar 
spongiotrophoblast specific (SSP) protein in rats143 are exclusively expressed in the placenta 
tissue. However, these genes have been found only in rodents. In humans, placenta-specific 
protein 1 (PLAC-1) was identified to have enriched expression in the placenta tissue. 
However, recently its expression has been found in human testis as well.144 Orthologous 
genes of PLAC1 have been discovered in cow, rat and mouse placenta tissue. Biological 
function of PLAC1 has not been defined yet, but it is thought to be linked with trophoblast 
differentiation and fibroblast growth factor (FGF7) signaling in the placenta tissue.145,146  
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Throughout human evolution most of the endogenous retroviruses (ERVs) have gone through 
a lot of modifications that have restricted their transcription. However, numerous endogenous 
retroviruses (ERVs) have intact open reading frames (ORFs) of their genes and are 
expressed.147,148 Among them, the best characterized genes are Syncytins and ERV-3 that 
have been acquired from the envelope gene of the endogenous retroviruses (ERVs). The 
envelope gene plays a critical role in the human placenta development, such as executing the 
process of cell fusion to form the syncytiotrophoblasts, regulating the immune response 
generated against the fetus, and restricting the chances of getting infected by exogenous 
viruses.149,147 ERV-3, despite its expression in the syncytiotrophoblasts, is not only considered 
as a fusogenic protein. Relatively, ERV-3 has been demonstrated in the differentiation of 
trophoblasts and regulation of human chorionic gonadotropin (hCG) expression in the 
placenta tissue.147  
The most expressed placenta-specific genes are human Syncytin genes, Syncytin-1 and 
Syncytin-2, derived from envelope genes of endogenous retroviruses HERV-W and HERV-
FRD. Due to their fusogenic ability, they induce the establishment of the multinucleated 
syncytiotrophoblasts in the placenta tissue.134,147,150 Syncytin-1 is expressed in the 
syncytiotrophoblasts throughout the pregnancy (Figure 5).125,116,148,151 However, Syncytin-2 is 
different from Syncytin-1, although they share similarity in their sequences and the ability to 
fuse the cells. Syncytin-2 additionally contains a protein domain that suppresses the maternal 
immune system and protects the embryo.116 Syncytin-2 is not localized to 
syncytiotrophoblasts, however its expression was also found in a subset of villous 
cytotrophoblast cells.152,153 In contrast to Syncytin-1, the levels of Syncytin-2 declines 
significantly at term.152 The differences indicate their diverse role in the human placenta 
tissue. Similar to the human Syncytins, mice have autonomously obtained retroviral envelope 
proteins from a distinct endogenous retrovirus (ERV) family; known as syncytin A and B.115 
They are exclusively expressed in the placenta tissue and function as a fusion protein.115 In 
the mouse placenta, they are primarily localized in the labyrinth layer containing 
syncytiotrophoblasts.115 The example of the mouse and the human syncytin genes indicate the 
function of ERV-derived genes in the development and evolution of the placenta and possibly 
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1.12.2. Placenta-specific promoters and enhancers co-opted from human endogenous 
retroviral LTRs (ERV-LTRs) 
 
In humans, certain genes are broadly expressed in most of the tissues of the body. However, 
in placenta, their expression has been found to be elevated or sometimes a placenta-specific 
isoform has been detected, mainly due to the co-option of an ERV-LTR element near the 
regulatory region of the genes (Figure 5).132,154 As mentioned before, the human ERV-LTRs 
are structurally enriched in the transcription factor (TF) binding sites, they utilize these LTR 
sequences for their own replication by using the host cellular factors.102 Co-option of a single 
ERV-LTR as a promoter, enhancer or both has been reported to drive the tissue-restricted 
expression by providing a novel regulatory sequence.155  
The human CYP19 has been evolved to utilize several promoters in different tissues.156 
Placenta-specific promoter of human CYP19 has been characterized as MER21A, which is 
derived from an ERV-LTR.157 The exponential expression of CYP19 in human placenta is as 
a result of the co-option of MER21A. It encodes for aromatase, a steroidogenic enzyme that 
converts androgens to estrogens and regulates the growth of the maternal uterus and the 
placenta and also plays a vital role in parturition.158,159 Different species (bovine, ovine and 
humans) have independently acquired their placenta-specific promoters for CYP19.160,161 
Conservation of CYP19 indicates its crucial role for pregnancy in all the mammals. Since, it is 
required throughout gestation so it seems that this requirement is fulfilled by the co-option of 
an ERV-LTR that was acquired during evolution. 
Some other genes involved in the human placenta development were identified to have 
increased placenta-specific transcription mediated by a unique tissue-specific promoter/ 
enhancer obtained from an LTR of HERV-E retroviral family. For example, the promoter/ 
enhancers of Opitz syndrome associated gene Midline1 (MID1), endothelin receptor B gene 
(EDNRB) and human growth factor pleiotrophin gene (PTN). The reason behind the placenta-
specific transcription of PTN is mainly due to the generation of an exclusive binding site for 
Sp1 (a transcription factor for estrogen receptor) due to the insertion of an ERV-LTR. PTN is 
expressed in different sub-types of trophoblasts and is known to regulate trophoblast life cycle 
and placental angiogenesis.162 Human ERV-LTR associated with EDNRB contains binding 
sites for Thing1/Hand1 that is required for the early trophoblast differentiation. Due to the 
available binding site on the human ERV-LTR it drives the placenta restricted expression of 
the EDNRB. Endothelin besides their role in vasodilation or vasoconstriction, mediate 
trophoblast proliferation and invasion through the Endothelin B receptor in humans.163 The 
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sequences of the human ERV-E LTRs associated with EDNRB, PTN and MID1 genes are 
highly similar, but the promoter/enhancer activity varies in terms of the tissue specificity and 
intensity of the gene expression. However, they provide unique transcription factor (TF) 
binding sites and their selective DNA methylation in placenta (as compared to other tissues) 
have contributed to the placenta-restricted expression of the genes. 5,164,132,165,166  
Another gene, Leptin is immensely expressed in the human placenta tissue and MER11 
(ERV-LTR) has been identified as its placenta-specific enhancer.131 Leptin prepares the uterus 
for parturition and establishes the lactating state of pregnancy. In human trophoblasts, it 
promotes cell proliferation and survival.167 Orthologous genes of human Leptin, EDNRB, and 
Pleiotrophin have been identified in the placentas of rodents but their expression is not 
mediated by an ERV-LTR.138 The sustenance of their expression in placenta is suggestive that 
these genes have preserved their function in the development of placenta tissue.168,169,170 
Placenta-specific expression of the early placenta insulin-like peptide 4 (INSL4) gene, in 
humans, is carried out by a primate-specific ERV-LTR of a HERV-derived sequence. Since 
the co-opted human ERV-LTR is near the TSS of INSL4, it gives additional features to the 
native gene promoter. The primate-specific ERV-LTR has also detected in the promoter of 
INSL4 homologue gene in the Rhesus Monkey.124 INSL4 has a robust expression during the 
initial phase of placentation and in differentiated syncytiotrophoblasts suggesting its role in 
placental morphogenesis.171,172 Similarly, the trophoblast-restricted expression of the 
Interleukin-2 Receptor beta subunit (IL2RB) has been reported to be mediated by a placenta-
specific promoter, derived from an ERV-LTR of the ancient domesticated THE1D retroviral 
family. IL2RB is required to establish a functional cytokine receptor for interleukin-2 (IL-2) 
or interleukin-15 (IL-15) signaling that is mediated at the maternal-fetal interface during 
placentation.173,174,175  
Some of the above discussed placenta-specific genes have been found to be dysregulated in 
PE patients. For example, dysregulated expression of INSL4, PTN, Leptin, and CYP19 have 
been reported before in PE patients.176,177,178,179,180 Currently, in humans a limited number of 
genes are known to be dysregulated in PE and have a placenta-restricted gene regulation 
mediated by an ERV-derived LTRs. Many more studies are required to identify such genes. 
Additionally, this would also help to understand the human-specific aspect of normal and 
abnormal placenta development as seen in PE patients. This study was focused on identifying 
new target genes that are highly expressed in the human trophoblasts, regulated by ERV-
LTRs and dysregulated in PE patients.  
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1.13. Objectives of the study 
 
PE has only been observed in humans and not in non-human primates. The underlying 
mechanisms of human-specific factors related to PE development are not well studied. In this 
study, I focus on the identification of new PE associated genes that are regulated by human 
endogenous retroviral LTRs (ERV-LTRs) and are predominantly expressed in the trophoblast 
cells. This strategy has not only identified already known genes but also new candidate genes 
contributing to PE pathogenesis. 
 
The aim of the thesis was further divided into the following hypotheses: 
1. Human ERV-LTRs contribute/ regulate the trophoblast-specific gene expression.  
 
It is known that the primate-specific ERV-LTRs are expressed in the human placenta due to 
low DNA methylation and their activation can lead to the possibility of regulation of genes 
located in their vicinity.5 In the project, one of the focus areas was identification of the role of 
human ERV-LTRs in trophoblast-specific gene regulation and understanding of human-
specific nature of PE development. RNA sequencing was performed on the primary human 
trophoblast cells of 5 healthy and 5 early-onset PE placentas. Genes that were enriched in the 
trophoblast cells as compared to other 38 human body tissues were identified. The expression 
analysis of TEs belonging to different families was done in human tissues. TEs enriched in 
placenta tissue were then selected for further analysis. RNA-seq analysis identified genes that 
have stronger expression in trophoblasts and showed co-regulation of expression with the 
human ERV-LTRs located in their vicinity (10-kb upstream of transcription start side (TSS) 
of the gene. The focus was on the human ERV-LTRs that were found to be transcriptionally 
active in the placenta tissue. The aim was to confirm the trophoblast-specific gene expression 
by q-PCR on pregnancy-related tissue panel samples and to investigate the expression of 
candidate genes in trophoblast sub-types by analysis of online available RNA-seq data of 
single-cells obtained from human placenta tissue. The potential activity of the human ERV-
LTRs associated with the trophoblast-specific gene was predicted by ChIP-seq data available 
for active histone marks and transcription factors important for trophoblasts differentiation, 
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2. The second working hypothesis was that the genes that are exclusively expressed in 
trophoblast cells or have trophoblast-specific gene regulation due to the associated ERV-LTR 
might have a predominant role in the development of human placenta tissue and their 
dysregulation might lead to pregnancy-related disorders such as PE. 
 
Here the aim was to validate the dysregulated expression of trophoblast-specific genes by q-
PCR on human PE patient samples of Oslo-cohort-II, consisting of 28 healthy, 24 early-onset 
PE and 22 late-onset PE patients. To gain deeper insight into the functional analysis of the 
novel candidate genes in PE pathogenesis, EPS8L1 was further investigated. Moreover, the 
trophoblast-specific localization of EPS8L1, its expression in human placental villi, EPS8L1-
protein interactors in trophoblast cell lines and the role of EPS8L1 overexpression (in-vitro) in 
SGHPL-4 cells (EVT-like) was investigated by functional assays.  
 
Collectively, the strategy was successful in identification of additional genes, regulated by 
human ERV-LTRs in trophoblast cells. As an example, the function of a previously 
uncharacterised gene EPS8L1 with an important role in human placenta development and how 
its dysregulation is related to the development of PE was demonstrated. 
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2. Materials and methods 
2.1. Materials 
 
2.1.1. mRNA isolation, quantitative polymerase chain reaction (q-PCR)  
 
QIAzol Lysis Reagent                                                                                     (QIAGEN) 
RNeasy Mini Kit                                                                                             (QIAGEN)  
Direct-zolTM RNA MiniPrep                                                                 (Zymo Research)  
High Capacity cDNA Reverse Transcription Kit                           (Applied Biosystems)  
TaqMan Fast Universal                                                                  (Applied Biosystems)  
Fast SYBR Green Master Mix                                                       (Applied Biosystems)  
Aglient RNA 6000 Nano Kit 
TruSeq Stranded mRNA LT Set A kit                                                              (Illumina) 
 
2.1.2. Primers and sgRNAs 
 
The primers and oligonucleotides for quantitative polymerase chain reaction (q-PCR) were 
designed using Primer Express ®ABI PRISM software. Some of the primer sequences were 
taken from public resource for q-PCR primers, primer bank MGH-PGA. Primers for cloning 
were designed either using the NEBuilder Assembly Tool or manually and were checked 
according to the general guidelines for primer design and best practices. The sgRNAs for 
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Table 1. Primers and sgRNA  
 
 Gene Primer Sequence (5’ > 3’) 
q-PCR ALDH3B2 Forward  ATGAAGGATGAACCACGGTCC 
Reverse  GTTCCAGGGTGCGATGATGA 
CSF2RB Forward  CTCGTCAACGTGACCCTCAT 
Reverse  CGACAAAACTCTGGCAGGGA 
CYP11A1 Forward  CTTCACCCCATCTCCGTGAC 
Reverse  GTCTTTGCTCAGCCATCGG 
PHYHIPL Forward  GTGCAGACTGCCTCAAAACA 
Reverse AAAACTTAAGCATGCGTCCTG 
SPINT1 Forward  AAGGTACAACCCCAGGAACC 
Reverse  CCTCTGGGTGGTCTGAGCTA 
DACT2 Forward  CGGTCGGTTGATGAGACTACT 
Reverse  CAGGGCTCTGTCAAGATCACC 
SLC22A11 Forward  TATTAAGGGCAAACCAGACCAAG 
Reverse  CCAGCCCATAGTAGGAGATCAA 
EPS8L1 Forward  GAGAGCTTTGTATCGAGGCTG 
Reverse  GCCCGAAAAGGAAGTGCAAC 
PLEKHA8 Forward  AGCCTCGATGGTTCCTTCTCT 
Reverse TCAGGTCCATGCGTGTATTATCT 
RAD51 Forward CAACCCATTTCACGGTTAGAGC 
Reverse  TTCTTTGGCGCATAGGCAACA 
KIF23 Forward TGGTTCCTACATTCAGAAATGAGA 
Reverse  CGTTCTGATCAGGTTGAAAGAGTA 
NRK Forward  CATTGGCCTTGGTACTTATGGC 
Reverse  GTCTTACGAGCGTTCATCACTT 
C1QTNF6 Forward  GAAAGGGTCTTTGTGAACCTTGA 
Reverse  CTGCGCGTACAGGATGACAG 
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EPS8 Forward  TGAATGGCTACGGATCATCACC 
Reverse  CACTGTCCCGTGCATAATTCT 
MYC Forward  GTCAAGAGGCGAACACACAAC 
Reverse  TTGGACGGACAGGATGTATGC 
CCND1 Forward  GCTGCGAAGTGGAAACCATC 
Reverse  CCTCCTTCTGCACACATTTGAA 




18S Forward  ACATCCAAGGAAGGCAGCAG 
Reverse  TTTTCGTCACTACCTCCCCG 

















Forward  CCCGGAGCGCCGGCGGCTGTC 
hEPS8L1-
EcoRV 




































































Forward ACAATTACCGCTCGGGCCGC  
hEPS8L1-
F2 
Forward GAGGCCGAGTACACCGACGT  






























Table 2. Antibodies used in the study 
 
Technique  Antigen  Host Conjugate  Dilution Manufacturer 
Western blot hEPS8L1  Rabbit  - 1:250 Atlas 
Antibodies 
Actin Mouse  - 1:5000 Dianova 
Rabbit 
IgG  




Goat  HRP  1:5000  Thermo 
Scientific  




- - - Lab Vision  
Immunostainings hEPS8L1 Rabbit - 1:100 Atlas 


















2.1.3. Western blot 
 
• RIPA buffer:  
 0.05 M Tris-HCl pH 7.4  
 0.150 M NaCl  
 0.001 M EDTA  
 1% Triton-X100  
 1% Na-Deoxycholate  
 0.1% SDS  
 Complete Protease Inhibitor Cocktail Tablets                           (Roche Diagnostics)  
• 6X SDS loading buffer:  
 3 ml Glycerol  
 1.5 ml B-Mercaptoethanol  
 9 ml 10% SDS  
 1 M Tris-HCl (pH 6.8)  
 Bromophenol Blue (pinch)  
 Adjust to 10 ml water  
• TEMED                                                                                                                
• APS                                                                                                                       
• Triton X-100                                                                                                       (Sigma)  
• Skim milk powder                                                                                                (Fluka) 
• Page Ruler™ Plus Prestained protein ladder                                    (Thermo Scientific)  
• TGX stain free FAST cast acrylamide gel kit                                                  (Bio-Rad) 
• Trans-Blot Turbo midi-size transfer stacks                                                      (Bio-Rad) 
• Trans-Blot Turbo midi-size PVDF membrane                                                 (Bio-Rad) 
• 1X Transfer buffer:   
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 5X TransBlot Turbo transfer buffer 200 ml   
 600 ml of Mili-Q H20 
 200 ml of ethanol 
• 10X TBS: 
 0.5 M Tris  
 1.5 M NaCl  
 1 L Mili-Q H20  
 pH 7.5  
• 1X TBS-T: 
 1/10 TBS  
 0.1% Tween 20  
• Mild stripping buffer:  
 0.2 M Glycine  
 0.1% SDS  
 1% Tween-20  
 pH 2.2  
2.1.4. Flow cytometry  
 
 Fix/ Perm buffer                                                                              (BD Biosciences)  
 Perm/ Wash buffer 10X                                                                  (BD Biosciences)  
 1 % PBS/ FCS (v/v)  
2.1.5. Immunostaining and immunohistochemistry  
 
 0.1 M Citrate buffer (pH 7.0) 
 Ultra V block                                                                                          (Lab Vision) 
 0.05 % PBS-T (v/v) 
 DAPI                                                                                                               (Sigma) 
 ProLong Gold Antifade Mounting Medium                                (Life Technologies) 
 Aminoethylcarbazole 45 Chromogen                                              (Lab Vision) 
 Kaiser’s Glycerol Gelatine                                                                             (Merck) 
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2.1.6. Isolation of primary human trophoblasts  
 
• HBSS/ HEPES (25 mM HEPES): 
 100 ml 10X HBSS (Hanks Balanced Salt w/o Phenol red, with Ca, Mg)      (Gibco)  
 5.958 g HEPES                                                                                               (Gibco) 
 900 ml H2O dest.   
 Set pH on 7.4 with NaOH  
• DMEM/ HEPES (25mM HEPES): 
 500 ml DMEM                                                                                                (Gibco)  
 2.9788 g HEPES  
 Set up pH on 7.4 with NaOH and sterile filtrate  
• Buffer 1a:  
 285 mg Trypsin                                                                                              (Sigma)  
 20 mg DNase I                                                                                                (Roche)  
 225 ml warm HBSS/ HEPES  
• Buffer 1b: 
 10 mg DNase I  
 25 ml warm HBSS/ HEPES  
• Buffer 2: 
 190 mg Trypsin  
 10 mg DNase I  
 150 ml warm HBSS/ HEPES  
• Buffer 3: 
 150 mg Trypsin  
 10 mg DNase I  
 110 ml warm HBSS/ HEPES  
• Buffer 4: 
 10 mg DNase I  
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 100 ml DMEM/HEPES  
• Dilution of New Born Calf Serum (Biochrome) (45 ml NBCS and 7.5 ml H2O dest.) 
• HBSS/HEPES for Percoll (10X HBSS w/o Ca, Mg and 250 mM HEPES)  
• 90 % Percoll (5 ml HBSS/ HEPES for Percoll and 45 ml Percoll)        (GE Healthcare) 
Table 3. Percoll gradient for trophoblast isolation 
 
 g/ml  90% Percoll  HBSS/HEPES  
70%  1,084  3,107 ml  0,893 ml  
60%  1,071  2,667 ml  1,333 ml  
50%  1,0595  2,227 ml  1,773 ml  
40%  1,0485  1,773 ml  2,227 ml  
30%  1,0375  1,333 ml  2,667 ml  
20%  1,0270  0,893 ml  3,107 ml  
 
• Monoclonal Mouse Anti-Human HLA-ABC Antigen                      (Dako Cytomation) 
• Dynabeads Pan Mouse IgG                                                                     (Dynal Biotech) 
• SmBM Basal medium + SmGM-2 Single Quot Kit Suppl & Growth Factors    (Lonza) 
2.1.7. Cell transfection 
 
jetPRIME DNA Transfection Reagent                                                             (PolyPlus) 
Lipofectamine™ 3000 Transfection Reagent                                                (Invitrogen) 
NEON™ Transfection System                                                          (Life Technologies) 
2.1.8. Mass spectrometry 
 
• Lysis buffer: 
 50 mM TRIS-HCL (pH:8.0) 
 100 mM NaCL 
 10 uM EDTA 
 5% Glycerol 
 1% NP-40 
 Benzonase and Protease inhibitor were added fresh 
• Washing buffer (10X lysis buffer): 
 5 mM TRIS-HCL pH 8.0 
 10 mM NaCL 
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 1uM EDTA 
 0.5% Glycerol 
 0.5% NP-40 
• Pre-elution buffer: 
 200 mM KCL 
 10 mM TRIS-HCL pH 8.0  
• Ezview Red Anti-HA Affinity Gel                                                   (Sigma Aldrich) 
2.1.9. Reagents and kits for assays 
 
• DCFH (2`7`-Dichlorofluorescin)                                                                  (Sigma)  
• Human EPS8-like 1 ELISA Kit (MBS9317820)                               (MyBioSource) 
• Recombinant Human Epidermal Growth Factor (hEGF)                         (Peprotech)  
2.1.10. Chemicals  
 
Chemicals were ordered from the following companies: Karl Roth GmbG & Co. KG, Jena 
Bioscience, Merck KGaA, Sigma-Aldrich GmbH, Amersham-Pharmacia, Invitrogen, Qiagen, 
GE Healthcare, BD Bioscience and Thermos Fischer Scientific. 
2.1.11. Software  
 
• 7500 Fast System SDS Software                                                   (Applied Biosystems)  
• Prism Version 7                                                                                              (GraphPad)  
• ImageJ/ Fiji                                                                      (GNU General Public License)  
• Primer Express 3.0                                                                         (Applied Biosystems)  
• Flow Jo                                                                                                      (TreeStar Inc.)  
• BD FACS Diva                                                                                     (BD Biosciences)  
• Case Viewer                                                                                             (3DHISTECH) 
• NEBuilder Assembly tool v2.2.6                                               (New England BioLabs)       
• CRISPOR                                                                                        (Tefor infrastructure) 
• Image Analysis Software                                                                                (Wimasis) 
2.1.12. Hardware  
 
• NanoDrop Spectrophotometer ND-1000                                                          (PeqLab)  
• 7500 Fast Real-Time PCR System                                                (Applied Biosystems)  
• FACS Caliber system                                                                           (BD Biosciences)  
• LSM710 point-scanning single photon confocal microscope                              (Leica) 
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• FACS Aria II                                                                                        (BD Biosciences) 
• FACS Aria III                                                                                       (BD Biosciences) 
• ChemiDoc MP V3 Western workflow                                                             (Bio-Rad) 
• Neon electroporation transfection system                                        (Life Technologies) 
• Microplate reader GENios plus                                                                            (Tecan) 
• EVOS Imaging System                                                       (Thermos Fischer Scientific) 
• Aligent 2100 Bio Analyzer machine                                                                  (Agilent) 
2.2. Methods  
 
2.2.1. Patient cohorts  
The following cohorts were used in this study. 
1. Oslo cohort:  Microarray data analysis of human placental samples has been 
published before comprising of PE patient samples from the bio-bank collection at Oslo 
University Hospital, Norway, authorized by the Regional Committee of Medical Research 
Ethics in Eastern Norway.181,182 Results were verified in a second cohort that consists of 
placental tissues collected following C-section from PE patients (n=50) and controls (n=28) 
with normal blood pressure and uncomplicated pregnancies. The PE group was further 
divided into early-onset PE (< 34 gestational weeks, n = 26) and late-onset PE (> 34 
gestational weeks, n = 24). The control group included healthy, normotensive women 
undergoing cesarean section due to breech presentation or other reasons. For validation of the 
differentially expressed genes in PE (Table 9), I used samples of this cohort consisting of 
control (n = 28), early-onset PE (n = 24), late-onset PE (n = 22) and IUGR+ PE (n= 6). All 
the quantitative PCRs were performed on the same set of samples, however some samples of 
this cohort were used up already and were not enough to be tested. Patient characteristics are 
shown in Table 4. The expression level of EPS8L1 in the placenta tissue isolated from the 
patients was correlated with the sFlt1/ PIGF ratio which is the prognostic marker for PE, and 
also with the gestation age (GA) of the PE patients and controls. The serum levels of PIGF 
and sFLT1 of the patients were detected from the second PE cohort on Elecsys (Roche 
Diagnostics) at HELIOS Klinikum GmbH. 
 
Table 4. Clinical characteristics Oslo cohort 
Clinical characteristics of PE patients and healthy controls. Data are presented as mean ± 
standard deviation, BMI: body mass index.  




2. Charite and Kiel cohort: The samples from Charite and Kiel cohort were used 
additionally to validate the dysregulation of EPS8L1 in PE patients by using q-PCR (Figure 
12). The samples from two cohorts were merged and the clinical characteristics are shown in 
Table 5. All PE samples are gestational age matched with their controls. 
 
Table 5. Clinical characteristics Charite and Kiel cohort 
Clinical characteristics of the PE, IUGR and control cases from the study population. Early is 
defined as delivery < 34 gestational weeks. Late is defined as delivery  ≥ 34 gestational week. 
Data are presented as mean ± standard deviation, BMI: body mass index. *P<0.05; 
**P<0.001 vs. control. 




3. Manchester cohort (High risk pregnancy cohort): ELISA was performed on a total 
of 24 serum samples (Controls n=12, early-onset PE n=12) from this cohort. All controls had 
a history of hypertension and some of the control cases had diabetes as well. Early-onset PE 
samples included those who developed PE during pregnancy. Samples included for this study 
were from 24th - 28th weeks of gestation. The age of the patients included in this analysis was 
more than 18 years, belong to different ethnic backgrounds and had no smoking history. 
4. Berlin Menstrual Study cohort: Serum sample of 6 non-pregnant healthy females 
were used from this cohort for the EPS8L1 ELISA. The women in this cohort had no self-
reported medical history and the age of all the women was between 25-30 years of age. The 
samples were collected at MDC, Buch, Berlin. Women taking any medications (birth control 
pills) were not included in this study. 
5. Graz cohort: A total of 141 placental samples, 92 samples from early gestation and 
49 samples at term were analyzed by q-PCR for the EPS8L1 expression throughout the 
gestation (Figure 11). Women in this cohort had no self-reported medical history, no smoking 
habit and the age of all the women was more than 18 years of age.  
2.2.2. Primary human trophoblast isolation  
 
Human placental tissue samples from healthy and PE patients were collected at HELIOS 
Klinikum in Buch, Berlin as described earlier.183 Primary human trophoblasts cells were 
isolated from placental tissue of 10 pregnant women that included healthy (n= 5) and PE (n= 
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5) primary trophoblast cells. The Regional Committee of the Medical Faculty of Charité 
Berlin approved the sampling procedure.  
In this study, all the placentas were processed within 2 hours after the delivery. The whole 
placental tissue was washed with pre-chilled 0.9% NaCl buffer. The same buffer was used for 
all further tissue washing steps until the digestion procedure. The decidua parietalis and 
basalis were removed from the placental tissue as well as the umbilical cord. The whole 
process of dissection and cutting of the placenta tissue was carried out on ice. The tissue was 
cut into smaller pieces and washed twice with the buffer using sieve and 500 ml cylinder.  
The tissue was cut into smaller pieces until pale pink homogenous tissue was obtained. Small 
veins, capillaries, fatty and fibrotic tissue were removed and the tissue was further mashed 
and washed and then was transferred to two 50 ml falcon tubes (around 100g of tissue in 
total).  
Mashed tissue from both the falcons was transferred to Erlenmeyer flask along with Buffer 1a 
and the mashed tissue was continuously mixed by using magnetic stirrer at 37°C (For all 
buffers and reagents see Materials section). Buffer 1b was added after 10 minutes of 
incubation. After 10 minutes of continuous mixing, Erlenmeyer cylinder was tilted and 140 
ml of supernatant was aspirated. The supernatant was filtered through the gauze twice by 
changing cylinders and gauzes.  After that Buffer 2 was added to the undigested tissue and 
was continuously stirred. After the 20 minutes of incubation at 37°C, the supernatant was 
collected and divided into four 50 ml falcon tubes (around 35 ml each) and 3, 3 ml of New 
Born Calf Serum (NBCS) was added to the bottom of each falcon. Falcons were centrifuged 
(2500 rpm, 4°C) for 10 minutes, supernatant was removed and each of the pellets was 
resuspended with Buffer 4 to 35 ml of overall volume from 4 falcons. The whole volume was 
transferred into one falcon and put into 37°C water bath with shaking. After 20 minutes of 
digestion with Buffer 2, whole procedure was repeated and Buffer 3 was used instead of 
Buffer 2 and repeated once again to get at the end three falcons with cell suspensions. Percoll 
(90%) 10 ml was added to each of the 3 falcons and centrifuged (1500 rpm, RT) for 10 
minutes. Supernatant was discarded and the cell pellets were resuspended with cold DMEM/ 
HEPES (15 ml of overall volume). The total cell suspension of 15ml was placed onto the 
percoll gradient. Gradient was made by pouring 4 ml of different percoll solutions on top of 
each other, highest being 70% and the lowest 20% (Table 3). The gradient was made by 
pouring the percoll on the side of the 50 ml falcon which was placed tilt, using 10 ml pipette 
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at room temperature and after adding the cell suspension carefully, the mixture was 
centrifuged (3500 rpm, w/o breaks) for 20 minutes. 
After centrifugation, cells from the 3rd and 4th rings (counting from the bottom) were 
carefully aspirated by using syringe and transferred into 30 ml of cold sterile DMEM/HEPES. 
Cells were centrifuged (1000 rpm) for 10 minutes to remove percoll. Cell pellet was 
resuspended in 30 ml of cold DMEM/ HEPES and all further steps were performed in sterile 
conditions. Viable cells were counted by staining the cells with Trypan Blue staining dye. 
Cells were then centrifuged (1000 rpm) for 5 minutes, after removing the supernatant, cell 
pellet was resuspended in 10 ml of cold HBSS/B (BSA 0.1%) buffer. The selection of the 
trophoblast cells was made by adding (140 μl) mouse anti-human HLA-ABC (monoclonal) 
primary antibody and it was incubated for 30 minutes at 4°C (on a shaker, w/o light). After 
that 40 ml of HSBB/B was added and centrifuged for 10 minutes at 1000 rpm. In the 
meantime, beads (Dynabeads Pan Mouse IgG) were prepared, for that 500 μl of beads was 
transferred into 15 ml falcon. Afterwards, the falcon was placed onto the magnet and buffer of 
the beads was discarded and 2 ml of HBSS/B was added.  The mixture was stirred gently and 
was placed into magnet and the medium was discarded. Again 500 μl of HBSS/B was added 
to beads and mixed. The solution was added to resuspended cells after centrifugation in 8 ml 
of HSBB/B and incubated for 30 minutes at 4°C on a shaker. After the incubation time, the 
falcon with beads and cell solution was placed into the magnet for 3 minutes and cell 
suspension was carefully transferred to a new falcon tube. The suspension was then 
centrifuged at 1000 rpm for 5 minutes and pellet was resuspended in 30 ml of SmGM. The 
cells in the suspension were counted and the viability was also assessed. To confirm the 
trophoblasts cell purity, the cells were stained with cytokeratin-7 and positive cells were 
checked by flow cytometry. The primary human trophoblast isolation protocol gave us around 
92% of pure primary trophoblast cells every time. Cells were transferred into the flask 
containing complete SmGM medium and were kept overnight in the incubator at 37°C. After 
12-14 hours in the incubator, isolated primary trophoblasts were collected and stored at -80°C 
for further processing to isolate RNA, DNA and proteins.  
2.2.3. Primary human trophoblasts mRNA isolation and sequencing 
  
Trizol lysis reagent was used to isolate total RNA from primary human trophoblast cells 
isolated from 5 healthy controls and 5 early-onset PE patients. The procedure was according 
to the manufacturer`s protocol, by using Direct-zol TM RNA MiniPrep kit including on-
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column digestion with DNase I (Zymo Research). NanoDrop spectrophotometer ND-1000 
was used to determine the concentration of RNA and the quality of RNA was determined by 
using Aglient RNA 6000 Nano Kit and Aligent 2100 Bio Analyzer machine. The Illumina 
TruSeq Stranded mRNA LT Set A kit (cat. no. RS-122-2101) was used to prepare library for 
RNA sequencing by using 550 ng of total RNA. Sample-specific indices were used to index 
all ten samples, which allowed for the sequencing of the five samples in two pools. The 
sequencing was performed as 100 bp first strand specific paired-end reads on an Illumina 
HiSeq 2000 platform of the BIMSB Genomics Platform of Max Delbruck Center for 
Molecular Medicine (Berlin, Germany). The clustering of the index-coded samples was 
performed on a cBot Cluster Generation System using PE TruSeq Cluster Kit v3-cBot-HS 
(Illumina).  
Sample-specific barcoded sequencing reads were de-multiplexed from multiplexed flow cells 
and the resulting BCL file was converted to the FASTQ format files using CASAVA 1.8.2. 
FastQC was used to analyze the quality of the raw reads 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). The reads having quality score 
below 30 were removed. Two nucleotides were truncated from either of the ends from 
sequencing reads, since their quality scores were inconsistent with the rest of nucleotides. 
This resulted in at least 70 million reads per sample (Table 6). Next, reads were mapped over 
the reference genome (Human hg19/GRCh37) and transcriptome model (hg19.refseq.gtf), 
downloaded from UCSC tables (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/) 
using Top Hat v2.0.8, sam tools 0.1.17.0 and Bowtie 2.0.5.0 applying parameters as: “tophat2 
-p 8 –r 150--mate-std-dev 140 -library-type fr-firststrand”. On average 75% of the total reads 
could be uniquely mapped to annotated gene models (Table 6). Approximately 10% of the 
reads were uniquely mapped on the repeated fraction of the genome. Cufflinks v2.08 was used 
to measure the transcript assembly as FPKM (Fragments Per Kilobase of transcript per 
Million mapped reads) for each individual sample. 
For calculation of differentially expressed genes (DEGs), we calculated counts per million 
(CPM) using FeatureCounts.184 We then implemented the algorithms from “DESeq2”, which 
performed the quantification and statistical inference of systematic changes between 
conditions, as compared to within-condition variability.185 The package “DESeq2” provides 
methods for testing differential expression by the use of negative binomial generalized linear 
models and the estimates of dispersion and logarithmic fold changes incorporate prior data-
driven distributions. In addition, for the outlier samples DEGs were calculated using a single-
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replicate model. The read counts were calculated with featureCounts from a subread package 
(http://subread.sourceforge.net/), FPKM was calculated using bamutils 
(http://ngsutils.org/modules/bamutils/count/). Next, the RandomVariable1 (Var1=nlx) 
formula was used. Where x, or Random Variable2, is the expression level of this gene, while 
n reflects the sequencing depth and l is the gene length. The two random variables used are 
from the published model of the “GFOLD” algorithm. This calculates the normalization 
constant and variance to extract fold changes from un-replicated RNA-sequencing data. The 
bioinformatics analyses of the RNA sequencing data were done in collaboration with 
Manvendra Singh, from the laboratory of Dr. Zsuzsanna Izsvák. 
Table 6. Human trophoblasts RNA sequencing results 
The number of total reads in each sample and number of uniquely mapped reads over genes. 





Sample001 75909926 56873255 
Sample002 74095582 55833441 
Sample003 75118812 57760827 
Sample004 71567772 51161663 
Sample005 71067420 53587259 
Sample006 79580464 60383151 
Sample007 76227398 56777791 
Sample008 71580658 52147477 
Sample009 83151188 62222722 
Sample010 79090178 59843244 
 
2.2.4. Trophoblast-specific genes (TSGs) and transposable elements (TEs) expression 
analysis 
 
RNA-sequencing data obtained from 10 samples of human primary trophoblast cells was 
compared to the online available data on brain, heart, liver, kidney and lungs to generate a list 
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of trophoblast-specific genes. The bioinformatics analyses were done in collaboration with 
Manvendra Singh, from the laboratory of Dr. Zsuzsanna Izsvák. The data, except the 
trophoblast RNA-sequencing data, was obtained from Illumina Human Body Map 2.0 (E-
MTAB-513) with 73-83 million 50 bp paired-end and 75 bp single-end reads from five 
normal non-placental human tissues (brain, heart, liver, kidney and lungs). RNA-seq data 
from human placenta was obtained from a published study which was performed in similar 
layout as the rest of the data sets analyzed.186 
All data was processed in similar fashion using the pipeline given above (Section: 2.2.3). At 
least 70-80% of the paired-end reads were uniquely mapped reads in each sample and were 
chosen for further analysis. Expression levels were calculated in Transcripts per million 
(TPM). Batch effect and other variations were removed by surrogate variance analysis. All 
samples were merged into one data frame by their genes. Low expressing genes, 
housekeeping genes and genes that didn’t show fluctuation (Mean/ (SD > 10)) were removed 
prior to analysis. Tissue specific genes were computed by ‘tau’ algorithms by setting cutoff to 
90%. 187 Similar set of analyses were performed for analyzing the expression of TEs in the 
above mentioned tissues. Average expression of any given TE family or locus was then 
calculated in CPM or RPKM. In this instance, we considered multi-mapping reads only if 
they were mapping exclusively within a TE family to estimate the TE family level expression 
in a given tissue. One alignment per read was employed to calculate the counts per million 
(counts normalized per million of total reads mappable on the human genome). The 
expression level of repeat families was calculated as Log2 (CPM+1) prior to comparison. Tau 
algorithms were then run to calculate tissue-specific TEs. 
In order to further evaluate the ability of TEs to modulate gene expression, we paired the 
expression level of TEs with the expression of the genes across 10 trophoblast samples.  
Correlation analysis (pairwise spearman ranked) was calculated for TEs and gene expression 
across the samples. This resulted in a matrix of correlational values between ~8000 genes and 
18000 TEs. We melted the matrix and obtained 1.44e+ 08 pairs. Finally, we classified them as 
high (r > 0.70) or low (< 0.70). To get the statistically significant pairs, a RandomForests 
(RF) models were coupled with a linear regression was used. To perform these tests a random 
genomic background, the negative control, and a training set, the reference, were generated. 
a) Training RandomForest for predicting TEs as distal promoters/ enhancers 
For this comparison a training dataset was generated together with a genome-wide map of 
distal DHS-to-promoter connectivity. The DHS data was acquired from an online source and 
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came from 79 cell lines.188 The genomic coordinates of distal DHS were extracted and 
intersected with the TE loci. Finally, we paired the obtained distal DHS-TEs with promoters 
based on their linkage value obtained from pairwise ranked correlations. We then classified 
them as high (> 0.70) or low (< 0.70). We used this classification to train cell line-specific 
RandomForests (RF). 
b)     RandomForest on paired data 
After generating gene-TE pairs across the analyzed tissues by the given classification, we 
used RandomForest, 189 gradient boosting machine (GBM) and support vector regression 
(SVR) algorithms to predict the gene expression levels linked to upstream TE. 
The above prediction algorithms were implemented in the R-packages of “RandomForest”, 
“gbm” and “e1071”. For the RF model, we set the parameter of n.trees = 500 (number of built 
trees) and selected the best mtry (number of variables randomly sampled as candidates at each 
split). For the SVR model, we selected the non-linear radial basis kernel. In the GBM model, 
we used the parameters [interaction. depth = 5,,n.trees = 5000, shrinkage = 0.01, 
n.minobsinnode = 10 and used Rsquared ] to select the optimal model with the largest value.  
We chose AUC > 0.70 as significant pairs. To investigate positional genomic relationships 
between TEs and trophoblast specific genes (TSGs), we filtered the TSGs. The list of 
significant pairs created troubleshooting as we found that several TSGs were served by TEs as 
their transcriptional start site (TSS) or transcriptional end site (TES). To overcome this 
threshold, the metric relationship of TE and TSS of protein coding genes was explored. The 
TE locus 10 kb upstream of the transcription start site of TSGs was arbitrarily defined to 
predict if a given TE is serving as the distal promoter/ enhancer for its neighboring gene. We 
fetched all endogenous retroviral LTR elements (ERVs) upstream of the TSGs whose pairing 
was significant. In search of drivers, the endogenous retroviral LTR elements (ERVs) which 
were over lapping with TSS, or were located within 1 kb upstream of TSS, were removed.  
Trophoblast-specific gene expression of the candidate genes was additionally analyzed across 
tissues catalogued by the GTEx consortium (PMID: 25954002). It consists of 32 tissues 
across 846 individuals. Trophoblast-specific upregulation was found to be consistent with the 
shortlisted candidate genes as compared to the rest of the human tissues.  
2.2.5. Quantitative polymerase chain reaction (q-PCR)  
 
Total RNA was extracted according to the manufacturer’s protocol from placenta tissue and 
trophoblast cells using QIAzol lysis reagent and Qiagen RNeasy Mini Kit (including on-
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column DNAase I digestion) (Qiagen). The quality and the concentration of the total RNA 
was measured by NanoDrop-1000 spectrophotometer (Peq Lab). The mRNA was converted 
to cDNA by using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
The real-time polymerase chain reaction (q-PCR) was performed on this cDNA to determine 
the expression of genes (Table 9) by using ABI 7500 Fast Sequence Detection System 
(Applied Biosystems). Data was analyzed by 7500 Fast System Software (Applied 
Biosystems). Primers and probes were designed with Primer Express 3.0 (Applied 
Biosystems) synthetized by Biotez (Germany) (Table 1). The expression of all of the genes 
was normalized to housekeeping genes (18S and GAPDH). 
2.2.6. Single cell RNA-seq (scRNA-seq) data analysis 
 
Human placental single cell RNA sequencing data (GEO accession: GSE89497; PMID: 
30042384) generated on SMART-seq2 platform was reanalyzed to estimate the expression of 
candidate genes in the trophoblast subtypes.190 The single cell RNA-seq analyses was done in 
collaboration with Manvendra Singh, from the laboratory of Dr. Zsuzsanna Izsvák. Reads 
were mapped to the human genome (hg19) using STAR (https://github.com/alexdobin/STAR) 
with the defined settings i.e. --alignIntronMin 20 --alignIntronMax 1000000 --
chimSegmentMin 15 --chimJunctionOverhangMin 15 --outFilterMultimapNmax 20 and only 
uniquely mapped reads were considered for the calculation of expression. Counts were 
obtained using FeatureCounts (http://subread.sourceforge.net/) at the gene level with Refseq 
annotations. Gene expression levels were calculated at Transcript Per Million (TPM) from 
counts over the entire gene (defined as any transcript located between the TSS and TES). This 
was done using our in-house R script (available on request). If a gene had a log2 TPM value 
above 1 it was regarded as expressed. We clustered the cells using the default parameters of 
the “Seurat” package from R. This applies to the most variable genes to get top 10 principle 
components, and the most discriminating genes cluster the cells on tSNE or UMAP. The 
major (cell/gene) clusters identified corresponded to Cytotrophoblasts, Syncytiotrophoblasts, 
Extravillous trophoblasts, macrophages and mesenchymal stromal cells. The cell type for 
each cluster was defined according to the known marker genes of trophoblasts and other cell 
types (Figure 21). 
2.2.7. Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) data analysis 
  
Publically available ChIP-seq data of chromatin marks for active and inactive regions 
(H3K9Ac, H3K27Ac, H3K4Me1 and H3K27Me3 (GEO accession: GSE127288 and 
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GSE118289)) during syncytiotrophoblast differentiation in primary culture and in human 
placental tissue was used. Further, ChIP-seq data on from the earliest trophoblast 
differentiation transcription factors (GATA2, GATA3, TFAP2A and TFAP2C (GEO 
accession: GSE105081; PMID: 29078328) was also used.191,192,193 The analyses was done in 
collaboration with Manvendra Singh, from the laboratory of Dr. Zsuzsanna Izsvák. 
The ChIP-seq datasets were downloaded in the raw FASTQ format.  ChIP-seq reads were 
aligned to the hg19 human reference genome using Bowtie2 (http://bowtie-
bio.sourceforge.net/bowtie2/manual.shtml) in the --very-sensitive-local mode. All unmapped 
reads, reads with MAPQ < 10 and PCR duplicates were removed using Picard and SAMtools 
(http://www.htslib.org/). All ChIP-seq peaks were called by MACS2 
(https://github.com/taoliu/MACS) with the parameters in the narrow mode for TFs and broad 
mode for histone modifications, while keeping FDR < 1%. Blacklisted regions were excluded 
from called peaks (https://www.encodeproject.org/annotations/ENCSR636HFF). The peak 
sets were intersected with repeat elements from hg19 repeat-masked coordinates using 
bedtools (https://bedtools.readthedocs.io/en/latest/) intersectBed with 50% overlap. To enable 
visualization through IGV over Refseq genes (hg19), the raw signals from the ChIP-seq were 
obtained from MACS2, using the parameters: -g hs -q 0.01 -B. The conservation track was 
visualized through UCSC genome browser under net/chain alignment of the given non-human 
primates (NHPs) and were merged beneath the IGV tracks.  
2.2.8. Cell culture 
 
Two trophoblast model cell lines were used in this study, choriocarcinoma line (BeWo) and 
transformed trophoblast lines, first trimester human extravillous trophoblast cell line 
(SGHPL-4). BeWo cells were maintained in DMEM/ F12-GlutaMAX supplemented with 
10% (v/v) FBS and 1% Antibiotic-Antimycotic (AA). SGHPL-4 cells were cultured in Ham`s 
F10 medium supplemented with 10% (v/v) FBS and 1% AA. Cells were cultured at 37°C in 
5% CO2. 
2.2.9. Genomic DNA extraction  
 
Frozen placenta tissues were pulverized with liquid nitrogen. According to the manufacturer’s 
instructions, genomic DNA from placentas was extracted using the DNeasy Blood and Tissue 
Kit (Qiagen, cat. 69504). Genomic DNA was stored at -20°C. Genomic DNA was used for 
amplification and cloning of the candidate endogenous ERV-LTR sequences.  
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2.2.10. ERV-LTR constructs  
 
Sequences of ERV-LTRs of all the candidate genes were downloaded from repeat masker 
from UCSC human genome browser version hg19. ERV-LTRs were amplified from genomic 
DNA of human placenta tissue by using sequence specific primers designed by using 
NEBuilder High Fidelity DNA assembly cloning tool (v1.12.15). Generated primers had 
overhangs with backbone of the plasmid. PT2-GFP reporter construct was used to clone the 
ERV-LTR upstream of the CAGs promoter by using Eco-RV site. A total of 9 constructs were 
generated and as a negative control a construct without an ERV-LTR was used for the assay. 
As an internal control an m-cherry construct having the same CAGs promoter was used. To 
calculate number of pmols of each fragment for optimal assembly, based on fragment length 
and weight, the following formula was used: 
pmols = (weight in ng) x 1,000 / (base pairs x 650 daltons) 
50 ng of 5000 bp dsDNA is about 0.015 pmols. 
50 ng of 500 bp dsDNA is about 0.15 pmols 
PCR was done on placental genomic DNA to amplify the ERV-LTR sequences by using 
Hybrid DNA polymerase (EURx) and vector backbone was digested with the Eco-RV 
restriction enzyme. HiFi DNA assembly reaction was setup by taking a ratio of 1:2 = vector: 
insert and total amount of the DNA was around 0.2 pmols. HiFi DNA master mix was used 
and the reaction mix was incubated at 50°C for 15 minutes. After incubation, ligation reaction 
was transformed into the Mix & Go (DH5α) cells. The colonies were picked after 24 hours 
and were sent for sequencing. The positive clones were then further sequenced to make sure 
there were no mutations in ERV-LTR sequence.  
2.2.11. GFP reporter assay 
 
Wild-type BeWo and SGHPL-4 cells were cultured for 24 hours in a 12-well plate. Retroviral 
LTR reporter constructs were transfected by using Lipofectamine 3000 Transfection Reagent 
according to the manufacturer’s protocol. M- Cherry construct was transfected in each well as 
an internal control along with ERV-LTR containing constructs. As a control, one well of plate 
was transfected with a GFP construct without any sequence, one with m-cherry construct 
only, one well with both the GFP and m-cherry constructs and one well remained un-
transfected. After 48 hours of transfection in the trophoblast cells, both GFP and m-Cherry 
signals were measured independently for each transfected ERV-LTR construct by flow 
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cytometry. FlowJo_V-10_CL software was used to analyze FACS data and the population of 
cells co-expressing both GFP and RFP was selected for analysis. The median florescence 
intensity (MFI) was calculated for the GFP signal and was normalized to the MFI of the m-
Cherry signal of each sample. The experiment was repeated 3 times with 3 technical 
replicates in each experiment.  
2.2.12. Western blot  
 
Equal numbers of cells were lysed using 6X SDS loading buffer and were cooked at 96°C for 
10 minutes. Denaturized proteins were separated on 10% SDS-PAGE gel. Proteins were 
electrophoresed in stacking gel with 90V until they reached resolving gel and then with 180V 
until the end. To transfer proteins from gel to PVDF membrane, trans-blot turbo transfer 
system was used. Membranes were equilibrated in 100% ethanol for 1 minute and proteins 
were transferred onto the membranes using trans-blot turbo transfer system 25V for 10 
minutes. Membranes were blocked with 5% w/v non-fat dry milk in TBS-T for 1 hour. After 
blocking, blots were incubated with needed concentration of antibody and incubated 
overnight at 4°C with gentle shaking. Secondary antibody conjugated with horseradish 
peroxidase was used and blots were incubated for minimum 1 hour, then membranes were 
developed with Amersham ECL prime western blotting detection reagent (GE Healthcare). 
Mild stripping buffer was used to strip the membranes (Abcam protocol), after that they were 
blocked again and incubated with loading control antibody. The antibodies used in the study 
and concentrations are mentioned in Table 2. ImageJ software was used to quantify the 
protein bands of EPS8L1 isoforms from western blot films. The quantification data shows the 
relative amounts as ratio of each isoform band relative to loading control (Actin) (Figure 
12C). 
2.2.13. Enzyme linked immunosorbent assay (ELISA) of EPS8L1 
 
Serum samples from Manchester cohort (high risk pregnancy cohort) were used to analyze 
EPS8L1 expression in PE patients as compared to healthy controls. Controls enrolled in this 
cohort had a prior history of hypertension and diabetes and had not developed PE later on 
during their pregnancy. Controls were gestational age matched with the PE patient and the 
gestational age (GA) was between 24th to 28th weeks of gestation. Serum EPS8L1 levels were 
analyzed in 12 PE, 12 healthy and 6 non-pregnant control serum samples according to the 
manufacturer’s instructions (MyBioSource, MBS9317820, USA). Non-pregnant serum 
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samples were collected in Berlin (Menstrual cycle study cohort). Each sample was tested 
twice for EPS8L1 levels and mean of the two measurements was used for statistical analysis.  
2.2.14. Immunohistochemistry (IHC) staining of primary villi and term placenta tissue 
(human) 
 
Paraffin embedded placenta tissue sections from healthy and PE patients were deparaffinized. 
Antigen retrieval was done by heat-induced epitope retrieval (HIER) method in 0,01M citrate 
buffer pH 6. Peroxidase activity was blocked with hydrogen peroxide (Lab Vision/ Thermo 
Scientific) for 10 minutes. Washing was performed by using tris-buffered saline with 0.05% 
Tween-20 (v/v) (TBS-T). To block non-specific immunoglobulin binding, ultra V Block (Lab 
Vision) was used for 7 minutes. Primary antibody (rabbit anti-EPS8L1 antibody (Atlas 
Antibody)) was diluted (1:250) in antibody diluent (Dako) and was incubated for 45 minutes. 
To identify non-specific tissue staining, antibody diluent without the primary (anti-EPS8L1) 
antibody was used as a negative control. Slides were washed 3X with TBS-T. After that, the 
secondary antibody conjugated with HRP polymer (ready-to-use; Lab Vision) was used and 
incubated for 20 minutes. Slides were incubated in dark with Aminoethylcarbazole 45 
chromogen (ready-to-use; Lab Vision) for 10 minutes and peroxidase activity was detected. 
Tissue sections were washed again with TBS-T and were counterstained with Haematoxylin 
for nuclei staining and mounted with Kaiser’s glycerine gelatine (Merck). Stained placenta 
tissue slides were analyzed by Dr. Martin Gauster from the Institute for Cell biology, 
Histology and Embryology of Medical University of Graz, Austria. 
2.2.15. Immunostaining of EPS8L1 in SGHPL-4 cells 
 
Equal number of (0.1 x 106 cells/ well) of WT-SGHPL-4 and OE-EPS8L1_SGHPL-4 cells 
were seeded on coverslips in a 12-well cell culture plates and incubated in 10% (v/v) FCS 
Ham´s F10 medium, 1% AA overnight at 37°C and 5% CO2. Cells were washed twice with 
PBS, then were fixed using 4% paraformaldehyde (Sigma) supplemented with Hoechst 33, 
342 (1: 250, Invitrogen) in PBS for 15 minutes and permeabilized with 0.1% Triton X-100 in 
PBS for 2 minutes. Cells were blocked by using 5% BSA in DPBS for 1 hour. Coverslips 
were then incubated with primary antibodies for actin and rabbit anti-EPS8L1 antibody 1:100 
(5% BSA prepared in PBS) overnight at 4°C then washed 3X with PBS and incubated with 
secondary antibodies Alexa Fluor 488 anti-rabbit (goat) and Alexa Fluor 647 anti-mouse 
(donkey) 1:200 for additional 1 hour. After extensive washes with PBS, nuclei were stained 
with DAPI solution (Vectashield with DAPI) for 10 minutes at RT in dark. After additional 
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washing, the samples were mounted using ProLong® Gold Antifade Reagent (Invitrogen) and 
images were taken using a Leica LSM710 point-scanning single photon confocal microscope. 
2.2.16. Knock-out (KO) of EPS8L1  
 
To study the effect of KO of EPS8L1 in trophoblast cells, CRISPR-Cas9 system was used and 
the protocol was followed as published by Broad Institute.194 The sgRNAs targeting EPS8L1 
were designed in silico by using CRISPOR Design Tool (http://tools.genome-
engineering.org). CRISPOR Design Tool identified suitable target sites to design oligos and 
primers for preparing sgRNA. The top three recommended oligos (phosphorylated) were 
ordered from BioTez. Top (100uM) and bottom strands (100uM) of phosphorylated oligos 
were mixed in ddH2O for annealing at RT for 30 minutes. The sgRNA oligo inserts were 
cloned into a plasmid backbone containing Cas9 and mVenus (gRNA Cas9 mVenus). 
Ligation reaction for each sgRNA was setup as mentioned in Table 7 and was incubated for 1 
hour (12 cycles of 37°C for 5 minutes and 21°C for 5 minutes). After incubation, the ligation 
mix was transformed into Mix & Go (DH5α) cells. Colonies were picked and after plasmid 
purification, the constructs were sent for sequencing. Three different guide RNAs were 
designed to access their ability to mediate targeted EPS8L1 cleavage.  Guide RNAs 
containing constructs were transfected into WT-BeWo cells along with a control plasmid 
having no insert. Transfection was performed by Lipofectamine 3000 (Invitrogen) 
transfection reagent according to the manufacturer’s instructions. After 48 hours, FACS was 
used to sort the GFP positive cells. After FACS sorting, the cells were cultured together in a 
dish for 5-7 days. Western blot was performed on total protein isolated from cells to confirm 
the KO of EPS8L1.  
Table 7. CRISPR reaction setup 
 
Components Amount(ul) 
Backbone (100ng) (Cas9 mVenus) 1 
Diluted oligo insert 2 
Cutsmart Buffer 10X 2 
DTT,10mM 1 
ATP, 10mM 1 
FastDigest BbsI 1 
T4 ligase 0.5 
ddH2O Up to 20ul  




2.2.17. Overexpression (OE) of EPS8L1  
 
To generate a stable overexpression of EPS8L1 in a trophoblast cell line, pT2B-puro Sleeping 
Beauty construct having the cassette (pCAGGS-HA-N-DLX5) was used. The expression 
construct contains an N-terminal Human influenza hemagglutinin (HA)-tagged human 
EPS8L1 open reading frame (ORF), driven by the ubiquitous CAGs promoter/ enhancer 
(chicken β-actin promoter/ enhancer coupled with the cytomegalovirus (CMV) immediate-
early enhancer). Puromycin cassette controlled by the SV40 (Simian virus 40) promoter was 
used for selecting cells containing the stably integrated transposon (Figure 16A). Puromycin 
selection was carried out for more than 12 days to strictly select for the stably expressing 
EPS8L1 cells. Human EPS8L1 coding sequence (Sequence ID: RefNM_133180.2) was 
amplified by PCR from placental cDNA with gene specific primers generated by NEBuilder 
HiFi DNA Assembly tool, harboring restriction sites for cloning into pT2B-puro Sleeping 
Beauty vector. PCR reaction was carried out with Kappa polymerase (Roche) on 50 ng of 
cDNA template from human placenta with 0.2mM dNTPs, 0.5μM primers, GC buffer (10 μl) 
in a final volume of 50 μl. Cycling conditions were: 95°C for 3 minutes, followed by 35 
cycles of 95°C for 20 seconds, 55°C for 20 seconds and 72°C for 3 minutes and final 
extension of 10 minutes at 72°C. The PCR product of ~ 2172 bp was extracted from 1% 
agarose gel; the vector backbone was digested with Eco-RV and Not-I restriction enzymes 
and was gel purified by using Qiagen gel purification kit. HiFi ligation reaction was prepared 
by using the gel purified plasmid backbone (0.05 pmol) and EPS8L1 amplified transcript 
(0.1pm) and mixed with HiFi mix (10 μl) and water (6 μl) and then incubated at 50°C for 30 
minutes. After incubation, the ligation mix was transformed to bacteria (DH5α) to clone the 
plasmid. Colonies were picked from the plate and sent for sequencing. The positive clone was 
then further sequenced to make sure there is no mutation in the coding gene sequence. 
2.2.18. Mass spectrometry (MS) of EPS8L1 
 
The protein interactors of EPS8L1 were determined by immunoprecipitation (IP) of HA-
tagged EPS8L1. HA tagged EPS8L1 was overexpressed transiently in WT-SGHPL-4 cells 
and WT-BeWo cells and the same construct without the HA tag was used as a control. 
Transfection was performed by Lipofectamine 3000 (Invitrogen) transfection reagent 
according to the manufacturer’s instructions. Three independent transfections were performed 
to have three biological replicates. After 48 hours, the cells were collected via cell scraper 
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without using trypsin. Cells were washed 2X with PBS and were centrifuged at 4000 rpm. For 
the last washing step 200 μl of PBS was added, from which 50 μl was used for the western 
blot analysis to confirm the transfection. Cell pellet was dissolved in 600 μl of lysis buffer 
(including benzonase). Cells were mixed gently and incubated on a shaker at 4°C for 40 
minutes. Cells were centrifuged at 14000 rpm for 10 minutes and the lysate was transferred 
into the new Eppendorf tube.  
In the meantime, beads (EZview TM Red Anti-HA Affinity Gel) were prepared. For 12 
samples, approximately 60 μl of beads per sample were used and washed with 5 ml of 
washing buffer twice (lysis buffer, 10X diluted). Centrifugation was carried out at 3000 rpm 
for 5 minutes. Washing buffer was added to make the final solution 2 ml along with beads. 
The washed red beads (160 μl) were added into the cleared cell lysate and incubated for 2 
hours at 4°C in the shaker. Supernatant was separated from the beads by centrifugation at 
3000 rpm. Beads were washed 4 times with 600 μl of washing buffer each time. 
Centrifugation was performed at 3000 rpm for 1 minute. After that, the beads were washed 
twice with pre-elution buffer (500 μl) and transferred to 1.5 ml new Eppendorf tubes. For 
protein elution, 300 μl of glycine (pH 2. 5) was added to the beads and incubated for 5 
minutes at room temperature with continuous rotation. Tubes were centrifuged at 3000 rpm 
for 10 seconds. Supernatant was transferred to the column with the filter and centrifuged for 
10 seconds. 15 μl of protein mix solution was used for western blot and the remaining 285 μl 
solution was precipitated by adding 70 μl of 2.5 NA, Acetate (pH 5.0) in each sample tube 
and each tube was filled with chilled ethanol (99%). Samples were stored overnight at 4°C. 
Tubes were centrifuged at 20,000 x g for 45 minutes at 4°C, ethanol was removed completely 
and the pellets were air-dried. Protein pellets were sent to the proteomics facility at MDC for 
mass spectrometry analysis. 
2.2.19. EPS8L1 overexpression (OE) and transcriptome analysis 
 
Wild-type SGHPL-4 cells were transfected with pT2B-puro Sleeping Beauty construct 
containing the EPS8L1 overexpression cassette to establish the stable overexpression in vitro 
model. When the cells reached 70% confluency after the 13th passage, they were washed 
twice with PBS without Ca2+ and Mg2+, and harvested with trypsin. The cells were collected 
in Ham´s F10 medium, 10% (v/v) FCS counted and centrifuged. After two subsequent PBS 
washing steps, total 1.4x105 SGHPL-4 cells were resuspended in 20 μl Resuspension Buffer R 
(Neon 10 μl, Invitrogen). The buffer also included a 10:1 ratio of the vector carrying the 
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EPS8L1 overexpression cassette (1 μg DNA), and the plasmid pcGlobin2-SB100X. With the 
latter containing the hyperactive Sleeping Beauty (SB) transposase (100 ng DNA) which 
facilitates the genomic integration of the vector. They were electroporated with the Neon 
Transfection System (Life Technologies), using the parameters: pulse voltage: 1260, pulse 
width: 20ms and number of pulses were 2. After the electroporation the cells were cultured in 
6-well plates after containing 2 ml Ham´s F10 medium with 10% (v/v) FBS. Two days post-
transfection puromycin was introduced (3 μg/ml) and used for 15 days to select for cells with 
successful integrations. EPS8L1 overexpression was confirmed by q-PCR and Western blot. 
Its expression and localization in the cells was determined by immunofluorescent staining. 
Transcriptome sequencing of EPS8L1-overexpressing SGHPL-4 cells (OE-EPS8L1_SGHPL-
4 cells) was performed by BGI on the BGISEQ-500 platform. Total RNA was isolated from 
the wild-type (WT) and OE-EPS8L1_SGHPL-4 cells using the RNeasy mini kit (Qiagen). 
Three independent transfections were performed and used as biological replicates. The 
minimum concentration of total RNA was 1000 ng of all the six samples that were sent to the 
company. All the samples passed the quality check RIN ≥ 7.0 28S/ 18S ≥ 1.0 and were 
processed for sequencing. After the sequencing run, the raw reads were filtered by BGI. Data 
filtering included removing adaptor sequences, contamination and low-quality reads from raw 
reads.  The statistics of data generated are shown in the Table 8A. Column description for 
data production is described in a separate Table 8B. 




Clean reads Clean bases Read length (bp) Q 20 (%) GC (%) 
BGI-1 63,310,194 6,331,019,400 100 97.64 % 49.98 % 
BGI-11 60,672,626 6,067,262,600 100 97.45 % 50.10 % 
BGI-3 71,589,886 7,158,988,600 100 97.72 % 50.49 % 
BGI-4 67,364,740 6,736,474,000 100 97.54 % 50.69 % 
BGI-6 67,534,274 6,753,427,400 100 97.62 % 50.82 % 
BGI-9 72,579,966 7,257,996,600 100 97.86 % 50.41 % 
B) 




Sample name Sample name that identify each sample 
Read length The length of the total reads (bp) 
Clean reads Total clean reads number 
Clean bases Total clean bases number 
Q20 % The number of nucleotide with quality higher 
than 20/nucleotide (clean read1, read2) 
GC % GC number / nucleotide (clean read 1, read 2) 
Original image data was transferred into sequence data via base calling, which is defined as 
the raw data or raw reads and was saved as FASTQ file. The bioinformatics analyses of the 
RNA sequencing data were done in collaboration with Manvendra Singh, from the laboratory 
of Dr. Zsuzsanna Izsvák. The methodology to calculate the differentially expressed genes is 
similar to the pipeline described in the data analysis of RNA isolated from human primary 
trophoblasts (Section = 2.2.3). 
2.2.20. Intersection of PE patients and OE-EPS8L1_SGHPL-4 cells datasets  
 
The transcriptome of the overexpressing EPS8L1-cells and PE patients was compared and 
analyzed. Two PE microarray datasets generated by Zadora et al. (2017) (PMID: 28904069) 
were used for this analysis. The data was analysed in collaboration with Manvendra Singh 
from the laboratory of Dr. Zsuzsanna Izsvák. A matrix of the expression levels for the unique 
genes in each sample was generated and the two datasets from different platforms were 
merged by their unique gene names for 24 PE and 22 control samples. The batch effect 
arising from two different platforms was corrected by normalizing surrogate variances from 
the “Combat” package from the R Bioconductor. The corrected batch effect was confirmed 
by a Principal Component Analysis (PCA). Each gene expression value was further assigned 
by their relative abundance value, which is the ratio of the expression level of a gene in each 
sample and the mean expression values of the gene across all the samples. Lastly, the EPS8L1 
gene was fetched from the obtained relative abundance matrix. A correlation analysis 
(Pairwise Spearman Rank) was performed on Log2 fold-change to identify the commonly 
dysregulated genes between the differentially expressed genes (DEGs) in the PEs vs controls, 
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and EPS8L1-OE vs controls. The DEGs were obtained by setting the criterion of the adjusted 
P-value at < 0.05.  
2.2.21. Invasion assay 
 
Transwell invasion assay was performed on OE-EPS8L1_SGHPL-4 cells and WT-SGHPL-4 
cells. The transwell inserts were pre-chilled and then coated with 50 μl of growth factor 
reduced matrigel (0. 25 mg/ml) diluted in Hams F10 w/o FBS. The plate containing the 
inserts was then incubated for 24 hours in a cell culture incubator at 37°C. OE-
EPS8L1_SGHPL-4 cells and WT-SGHPL-4 were serum starved by incubating them for 24 
hours in Ham's F10 media containing only 0.5% FBS and were incubated for 24 hours at 
37°C.After 24 hours, transwell inserts were prepared in two steps. In the first step, equal 
number of serum starved WT-SGHPL-4 cells and OE-EPS8L1_SGHPL-4 cells were plated 
onto the matrigel coated wells. Serum starved cells were rinsed with 5 ml DPBS (without 
Ca2+ and Mg2+), trypsinized by 1 ml trypsin and incubated at 37°C for 3-5 minutes and then 3-
4 ml of Ham’s F10 media with 0% FBS was added to the cells. Cells were counted by 
hemocytometer and centrifuged at 300 x g for 5 minutes. After removing the supernatant, 
cells were resuspended in 0% FBS Ham’s F10 to obtain the cell suspension concentration of 5 
x 105 cells /ml. From this suspension culture, 200 μl of cells (5 X 104) per well were plated 
onto the matrigel coated inserts. In the second step, chemoattractant was prepared. EGF (10 
ng/ml) was used as a positive control and was prepared in 10% FBS in Ham’s F10 and as a 
negative control 0% FBS in Ham’s F10 was used. Rest of the wells were filled with 750 μl of 
10% FBS/Ham’s F10 per well.  
Cells were incubated at 37°C for 12-14 hours for invasion assay. After 12-14 hours of 
incubation, invaded cells were fixed and stained. Media was removed from the top and the 
bottom of the insert; the inserts were washed twice with PBS. To fix the cells 3.7% PFA was 
added and the cells were incubated for 2 minutes at room temperature. Cells were washed 
again 2X with PBS to completely remove the PFA. For permeabilization, 100% methanol was 
added and the cells were incubated for 20 minutes at room temperature. The transwell inserts 
were washed twice and the cells both invaded and non-invaded were stained with 0.2% 
crystal violet. The plate containing the cells was covered with aluminum foil and then 
incubated at room temperature for 15-20 minutes. Cells were washed again after incubation. 
Non-invaded cells were scraped off by using cotton swabs. Images were taken under the light 
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microscope (bright field). Images were analyzed and invaded cells were counted by Fiji/ 
ImageJ software. Experiment was repeated at least three times.  
2.2.22. Tube formation assay (Angiogenesis assay) 
 
For the tube formation assay, u-slide angiogenesis (Ibitreat) were coated with 10 μl/ well 
growth factor reduced matrigel. A total of 8000 cells/well (50 μl/well) both OE-
EPS8L1_SGHPL-4 cells and WT-SGHPL-4 cells (control) were coated on to the matrigel and 
were incubated for 6 hours at 37°C. EGF was used to stimulate the tube formation 
(angiogenesis) and 0% FCS was used as a negative control. Images were taken after 6 hours 
and were analyzed by using the Wimasis Image Analysis software. Total number of tubes, 
tube length, loops and branching points were quantified by the software between OE-
EPS8L1_SGHPL-4 cells and WT-SGHPL-4 cells. Experiment was repeated at least three 
times.  
2.2.23. DCFH-DA assay (ROS assay) 
 
A total of 5 X 104 OE-EPS8L1_SGHPL-4 cells and WT-SGHPL-4 cells (control) per well 
were seeded on a 24-well plate in 1 ml of Ham´s F10 medium with 10% (v/v) FCS, 1% AA 
and were incubated for 24 hours in 37°C, 5% CO2. Cells were labelled with 0.05 mM DCFH-
DA for 45 minutes. DCFH-DA diffuses into the cell, becomes deacetylated by cellular 
esterases to non-fluorescent DCFH, which is then oxidized to fluorescent DCF by ROS 
(Figure 20A). GFP fluorescence intensity is proportional to the ROS inside the cell. After 
incubation, cells were washed 3 times with PBS, trypsinized and GFP signal was analyzed on 
FACS caliber system using Cell Quest Software. Data is presented as a median and mean 
fluorescent intensity (MFI) of the GFP signal. Experiment was repeated at least three times. 
2.2.24. Statistics  
 
Statistical analysis was performed with GraphPad Prism (GraphPad Software) and R 
Statistical Programming Language. Data are presented as either mean ± SEM (for normally 
distributed data) or median with inter-quartile range (for non-normally distributed data). 
Normal distribution was assessed by D'Agostino & Pearson omnibus normality test, Shapiro-
Wilk normality test and Kolmogorov-Smirnov tests. Data sets were compared using the 
Unpaired t-test, Mann–Whitney test, Wilcoxon-rank sum test, ANOVA and Kruskal-Wallis 
test as appropriate. Post hoc testing included Dunnet’s test and Dunn’s test for multigroup 
comparisons. Statistical correlation analysis between nonparametric variables was performed 
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using Spearman´s rank correlation. Techniques for each analysis are specified in the figure 
legends. Two-tailed testing with normal-based 95% confidence interval was performed for 






3.1. Search strategy to identify trophoblast-specific genes associated with ERV-LTRs  
 
To identify trophoblast-specific genes that are regulated by ERV-LTRs and are also 
dysregulated in PE patients, RNA sequencing (RNA-seq) data of human primary trophoblasts 
(done in our lab) was compared with the online available RNA-seq data on human brain, heart, 
liver, kidney, lungs and placenta tissue (Illumina Body Map and GTEx). The comparative 
analysis (as mentioned in methods section 2.2.4) generated a list of 335 genes that showed 
higher expression in the placenta tissue and trophoblast cells as compared to other tissues. To 
identify which trophoblast-specific genes (candidate genes= 335) are regulated by ERV-LTRs, 
first, the transposable element (TE) families that have enriched expression in the human 
placenta as compared to other human tissues including liver, lung, brain, kidney, heart and 
placenta were identified (Figure 6). The analysis identified certain TEs families to be enriched 
in the human placenta tissue, specifically. From the three clusters of TEs families that showed 
enriched expression in placenta tissue as shown in the heat map (Figure 6), I focused on those 
TE families that are also primate-specific, including endogenous retroviral elements (ERVs) 
(encircled in purple, Figure 6). In order to identify the role of TE-derived regulatory sequences 
as tissue-specific enhancers, a workflow was designed to identify those TE-derived sequences 
(primate-specific) that potentially performs a regulatory role in gene expression in human 
trophoblast cells. To find the TE-gene pairs (e.g. enhancer-target), the expression of the genes 
that showed higher expression in trophoblasts (candidate genes=335) was compared with the 
expression of the TEs located within 10-kb region upstream of the transcription start site (TSS) 
of the genes (as mentioned in methods section 2.2.4). This approach identified 88 genes that 
showed co-regulated expression with TEs inserted in the gene vicinity, suggesting that these 
TEs might be involved in regulating the neighboring trophoblast-specific genes.  
In addition, I asked whether the TE-derived dysregulation of genes might contribute to the 
pathology of certain pregnancy-associated diseases, e.g. PE. Thus, from the 88 genes, I focused 
on those genes that were dysregulated in PE patients. In order to identify the dysregulated 
genes in PE patients, microarray data of the published Oslo-Cohort-I (24 PE patients compared 
with 22 healthy controls) and RNA-seq data of primary human trophoblasts (early-onset PE 
patient’s (n=5) and healthy controls (n=5)) were analyzed and from the list of 88 genes, 16 




candidate genes were found to be associated with primate-specific endogenous retroviral LTR 
elements (ERV-LTRs) that were also found to be enriched in the placenta tissue and the 
trophoblast cells (Table 9). For further analysis, I focused on these 16 candidate genes as 
mentioned in the table 9. First I identified the real dysregulated candidate genes in PE patients 
and for that I analyzed the expression of the candidate genes in a bigger sample cohort that 
consist of 24 controls and 50 PE patients by q-PCR (Figure 7). Next question was to validate 
their trophoblast-specific gene expression and for that I established a pregnancy related tissue 
panel and analyzed the expression of the dysregulated candidate genes (Figure 8). In order to 
validate the potential activity of primate-specific ERV-LTRs associated with the genes, I 
performed GFP-reporter assay in the trophoblast cell line (Figure 9). Since my interest was to 
characterize the function of dysregulated ERV-LTR regulated trophoblast-specific genes in PE 
pathogenesis, so in this project, I focused on one candidate gene (EPS8L1) and identified its 







Figure 6. Expression of transposable elements (TEs) in human tissues  
Heat map displaying the scaled expression (Log 2 (counts per million+1) of 954 expressed TE 
families across the 6 human tissues (Illumina Body Map 2.0; E-MTAB-513). Each row 
represents a single TE family and columns represent tissues. Group of TE families are shown 
as 10 distinct k-means clusters on the basis of their dynamic expression. Given clusters are 
manually annotated by 10 TE families which show the variable expression across the tissues 
but enriched in the respective tissues. Color codes are used to match the clusters with their 
annotations. Encircled TE families (purple box) are those which are strongly expressed in 








Table 9. Short-listed trophoblast-specific genes with their associated ERV-LTRs 
Genes that are already known to be placenta-specific and have been reported to be 









3.2. Expression of trophoblast-specific genes in PE patients 
 
To validate the differential expression of candidate genes in PE patients, quantitative 
polymerase chain reaction (q-PCR) was performed on human placenta tissue samples of Oslo-
cohort-II (Control=28, early-onset PE=24, late-onset PE=22, IUGR+PE=6). Quantitative-PCR 
data indicated no significant differences in the gene expression of C1QTNF6, KIF23, RAD51, 
PLEKHA8, NRK, PHYHIPL and SLC22A11 in PE patients (early-onset and late-onset PE) 
when compared to healthy controls (NS: Not Significant; Kruskal–Wallis test; Dunn’s multiple 
comparisons test). (Figure 7A). In contrast, gene transcripts of CYP11A1 and CSF2RB were 
found to be significantly upregulated (**P< 0.001, *P< 0.01; 1-way ANOVA; Dunnett’s 
multiple comparisons) along with EPS8L1 (*P< 0.01; Kruskal–Wallis test; Dunn’s multiple 
comparisons test) in the early-onset PE patients as compared to the healthy controls, whereas 
the transcripts of SPINT1, ALDH3B2 and DACT2 were found to be significantly downregulated 
(*P< 0.01; Kruskal–Wallis test; Dunn’s multiple comparisons test) in early-onset PE patients as 
compared to the healthy controls (Figure 7B). In late-onset PE patients, increased expression of 
CYP11A1 (**P< 0.001; 1-way ANOVA; Dunnett’s multiple comparisons) and decreased 
expression of SPINT1 (*P< 0.01; Kruskal–Wallis test; Dunn’s multiple comparisons test) was 
detected as compared to the healthy controls. However, CSF2RB (1-way ANOVA; Dunnett’s 
multiple comparisons), ALDH3B2, EPS8L1 and DACT2 (Kruskal–Wallis test; Dunn’s multiple 
comparisons test) were not found to be significantly dysregulated in late-onset PE patients as 
compared to the healthy controls. Altogether, out of 16 short-listed candidate genes, q-PCR 










A) Quantitative polymerase chain reaction (q-PCR) did not show any significant differences 
in the gene expression of C1QTNF6, KIF23, RAD51, PLEKHA8, NRK, PHYHIPL and 
SLC22A11 in PE patients of Oslo-cohort-II as compared to controls (NS: Not Significant; 
values are as mean ± SEM; control n=28; early-onset PE n=24; late-onset PE n=22; IUGR+ 
PE n=6; Kruskal–Wallis test; Dunn’s multiple comparisons test). B) Quantitative polymerase 
chain reaction (q-PCR) confirmed increased mRNA levels of CYP11A1 and CSF2RB (values 
are as mean ± SEM; control n= 28; early-onset PE n=24; late-onset PE n=22) (**P< 0.001, 
*P< 0.01; 1-way ANOVA; Dunnett’s multiple comparisons), increased expression of EPS8L1 
(values are as mean ± SEM; control n= 28; early-onset PE n=24; late-onset PE n=22) (*P< 
0.01; Kruskal–Wallis test; Dunn’s multiple comparisons test) and downregulated expression 
of SPINT1, ALDH3B2 and DACT2 (values are as mean ± SEM; control n= 28; early-onset PE 
n=24; late-onset PE n=22) (*P< 0.01; Kruskal–Wallis test; Dunn’s multiple comparisons test) 
in early-onset PE patients of Oslo-cohort-II as compared to the control. 
3.3. Trophoblast-specific expression of dysregulated genes in PE  
 
The expression of shortlisted dysregulated genes in PE was analyzed in different tissues. The 
collective average expression of the six candidate genes (CYP11A1, SPINT1, CSF2RB, 
ALDH3B2, DACT2 and EPS8L1) was the highest in the placenta tissue as compared to the rest 
of the 38 human body tissues (GTEx data; PMID: 25954002) (Figure 8A) indicating their 
tissue-specific gene regulation.195 Quantitative-PCR was performed on human pregnancy-
associated tissue samples consisting of maternal muscle, fat, decidua, placenta tissues, primary 
human trophoblasts and Hofbauer cells (predominant macrophage cells of the fetus). The 
results (normalized with GAPDH) confirmed the enriched expression of the candidate genes in 
the placenta tissue and primary human trophoblast cells (Figure 8B). Gene transcripts of 
CYP11A1, CSF2RB and ALDH3B2 were also detected in the decidua but at lower levels 
(Figure 8B). 
In addition, scRNA-seq data analysis (GEO accession: GSE89497; PMID: 30042384) of 
human placenta tissue from 8th and 24th week of pregnancy further dissected the cell-type 
specific expression of the 6 candidate genes in human placenta (Figure 8C).190  The trophoblast 
sub-types were characterized based on the known marker genes for the specific cell-types as 
mentioned in Figure 21 in the supplementary information. Expression of all of the six genes 
were found to be enriched (*FDR< 2e-7) in at least one of the sub-types of the trophoblasts. 
For example, EPS8L1 is broadly expressed in the cytotrophoblasts and all the sub-types of 




expression levels were found in the syncytiotrophoblast cells. SPINT1 was also found to be 
expressed in most of the trophoblast subtypes, but the highest expression was detected in the 
cytotrophoblasts. Except cytotrophoblasts, CSF2RB was found to be expressed in almost all 
types of trophoblast with higher expression in the extravillous trophoblast cells of the second 
trimester. CYP11A1 expression was consistent in all the trophoblast sub-types. ALDH3B2 also 
showed stronger expression in syncytiotrophoblasts like EPS8L1. DACT2 was also found to be 
expressed in all the trophoblast cells (Figure 8C). The single cell analysis further confirmed the 
trophoblast-specific expression and localization of the candidate genes in the human placenta 
tissue. 
 
Figure 8. Trophoblast-specific expression of dysregulated genes in PE  
A) RNA-seq data analysis (GTEx data; PMID: 25954002) showed enriched (***P< 0.0001) 
expression of the six candidate genes including CYP11A1, SPINT1, CSF2RB, ALDH3B2, 
DACT2 and EPS8L1 in the human placenta as compared to other 38 body tissues. Boxplots 
shows the distribution of the scaled expression of candidate genes across different human 
tissues (row-wise z-score) The higher the Z-score, the more tissue-specific enrichment. B) 
Quantitative polymerase chain reaction (q-PCR) confirmed the higher transcript levels of the 




trophoblast cells compared to other pregnancy-related tissues (fat, decidua, muscle, 
macrophages and hofbauer cells). C) Expression of individual six candidate genes in single 
cellular transcriptome of human placental tissue (GEO accession: GSE89497; PMID: 
30042384). Violin plots showing the enriched expression of CYP11A1, EPS8L1, CSF2RB, 
SPINT1, ALDH3B2 and DACT2 across trophoblast lineages of the human placenta from 8th 
and 24th week of gestation (Log2 transcripts per million +1). (CTB/ VCT: cytotrophoblast, 
STB/SCT: syncytiotrophoblast, EVTs/ EVTB- (1-3): distinct populations of extravillous 
trophoblast at 8thW and EVTB-24W: extravillous trophoblast at 24th week), blood, 
macrophages and Hofbauer cells (macrophage-2)). Given candidate genes are significantly 
(*FDR < 2e-7) upregulated in either one or all of trophoblast lineages compared with the rest 
of cell types. 
3.4. ERV-LTR mediated trophoblast-specific gene regulation 
 
To delineate the potential cis-regulatory effect of the primate-specific ERV-LTRs associated 
with the candidate genes, the ERV-LTRs were analyzed initially for the transcription factor 
(TF) binding sites in differentiated trophoblasts (ChIP-seq).99 The transcription factors (TFs) 
(e.g. GATA3, GATA2, TFAP2A and TFAP2C) essential for the early trophoblast progenitor 
cells differentiation in-vivo and regulation of the trophoblast-specific gene expression were 
analyzed (GEO accession: GSE105081; PMID: 29078328).193 In addition, the active and 
repressive histone marks  (H3K4Me1, H3K27Ac, H3K9Ac and H3K27Me3) over the ERV-
LTRs were also analyzed from the data available on human placenta tissue at term (GEO 
accession:GSE118289; PMID: 30231016) and in differentiated syncytiotrophoblasts (GEO 
accession: GSE127288; PMID:31294776) (Figure 9A).191,192 The analysis detected at least one 
of the four trophectoderm-specific TF binding sites along with the active enhancer marks on 
the ERV-LTRs, suggesting the possible role of ERV-LTRs as enhancers for their downstream 
neighbor genes.  
To demonstrate the activity of the ERV-LTRs as potential enhancers, an in-vitro GFP reporter 
assay was established. GFP reporter constructs for each of the ERV-LTRs associated with the 
candidate genes were generated. Multiple upstream human ERV-LTRs of CYP11A1 and 
DACT2 were amplified and cloned individually in a reporter construct. The ERV-LTRs were 
amplified from the genomic DNA of the human placenta and cloned upstream of the CAGs 
promoter (Figure 9B). The enhancer assay revealed the highest reporter signal for the 
MLT1F2-2 located upstream of the CYP11A1 indicating its enhancer potential (Figure 9C). 




CYP11A1, suggesting that the trophoblast-specific CYP11A1 expression is likely regulated by 
an ancient ERV-LTR. Interestingly, the MLT1F2 sequence derived from the nearby locus of 
the ALDH3B2 generated a significant higher GFP signal whereas a similar sequence but located 
upstream of the SPINT1 was not significant (Figure 9C). In addition, MLT1G1, MLT1J, 
MLT1C and MER41D, located upstream of the ALDH3B2, EPS8L1, CYP11A1 and CSF2RB 
genes respectively generated significant GFP signal whereas MLT2B4 neighboring the DACT2 
had no significant enhancement of the GFP signal when compared to the control (Figure 9C).  
Collectively, the data recapitulate the enhancer potential of the ERV-derived LTRs that have 
been co-opted in the human genome and are conserved in the primates. Their activation in the 
human placenta can contribute to the trophoblast-specific gene regulation of certain genes 
located nearby. Notably, since the human ERV-LTRs are not in their native chromatin context, 
the reporter assay was not suitable enough to demonstrate the direct link between the cis-
regulatory activity of the ERV-LTRs and the endogenous expression of the downstream 
candidate genes.   
 




A) Integrative Genome Visualization (IGV) showing raw ChIP-seq signal on the ERV-LTRs 
associated with CYP11A1, SPINT1, CSF2RB, ALDH3B2, DACT2 and EPS8L1 for binding sites 
of active and repressive histone marks (H3K4Me1, H3K27Ac, H3K9Ac and H3K27Me3) in 
differentiated syncytiotrophoblasts (GEO accession: GSE127288; PMID: 31294776) and 
human placenta tissue at term (GEO accession: GSE118289; PMID: 30231016). Binding sites 
of master transcription factors that determines the trophoblast lineages including GATA2, 
GATA3, TFAP2A and TFAP2C (GEO accession: GSE105081; PMID: 29078328) found in 
trophoblast progenitors are also shown. Shaded boxes represent the repeat masked ERV-LTR 
sequences with active chromatin status around the candidate genes. Arrow shows the 
transcriptional start sites (TSSs) and orientation of respective genes. B) Schematic of the ERV-
LTR reporter constructs generated for the GFP-Reporter Assay. C) Bar-plot showing the 
Median Florescence Intensity (MFI) calculated by normalizing the GFP signal with the m-
cherry signal for the 9 ERV-LTR reporter constructs (shown in red) as compared to the control 
(construct w/o LTR, shown in blue). The data is from three independent experiments (*P < 
0.05; Unpaired t- test).  
3.5. Functional characterization of EPS8L1 in PE  
 
The candidate genes that were found to be dysregulated in PE patients have been known to 
mediate different biological processes in humans. Most of the genes have well characterized 
biological and molecular function, however, their association with the human ERV-LTRs to 
mediate the trophoblast-specific regulation and their dysregulation in PE patients of Oslo-
cohort-II is still novel and interesting to study. Several different biological roles of the 
candidate genes have been described earlier, for example, CYP11A1 (Cytochrome P450 
Family 11 Subfamily A Member 1) belongs to the family of enzymes that are involved in the 
steroid hormone production and it was found to be upregulated in PE patients.196 ALDH3B2 is 
involved in the metabolism of alcohol and high levels of ALDH3B2 has been detected in the 
human placenta.197 SPINT1 (Serine Peptidase Inhibitor, Kunitz Type 1) function as an 
inhibitor of hepatocyte growth factor (HGF) activator and has been reported to be essential for 
the development of the mouse placenta.198 DACT2 (Dishevelled Binding Antagonist of Beta 
Catenin 2) is involved in various signaling processes throughout the development (e.g.TGF-
beta signaling). CSF2RB (Colony Stimulating Factor 2 Receptor Subunit Beta) functions as 
the common receptor for IL-3, IL-5 and CSF and EPS8L1 is predicted to be the substrate for 




In PE data analysis, EPS8L1 was found to be the most significantly upregulated gene from the 
6 short listed genes in PE cohorts after the CYP11A1, which has already been associated with 
PE. EPS8L1 is an epidermal growth factor receptor pathway substrate 8 (EPS8) - like protein 
1. Its paralog, EPS8 is well studied and reported to mediate several pathways that are related 
to tumorigenesis, metastasis and proliferation of the cancer cells.199-203 Nevertheless, EPS8, by 
contrast to EPS8L1 was not found to be dysregulated in PE patients of the Oslo-cohort-II 
(Figure 10). Since EPS8L1 is a functionally uncharacterized protein and has not been 
previously associated with PE, therefore, in this study, I focused on the identification of the 
role of EPS8L1 in PE pathophysiology.  
 
Figure 10. Expression of EPS8 in PE patients 
Quantitative polymerase chain reaction (q-PCR) did not reveal any significant differences in 
the gene expression of EPS8 in PE patients (early and late-onset) of the Oslo-cohort-II as 
compared to the control (values are as mean ± SEM; control n=28; early-onset PE n=24; late-
onset PE n=22) (Kruskal–Wallis test; Dunn’s multiple comparisons test, NS: Not Significant). 
3.6. Expression and localization of EPS8L1 in human placenta tissue 
 
The trophoblast-specific expression and the localization of EPS8L1 were additionally analyzed 
by immunohistochemical (IHC) staining on the human placenta tissue. A healthy human 
placenta tissue at term and first trimester placental villi were stained. In conjunction with the 
single-cell transcriptome data, EPS8L1 expression was detected in different types of the 
trophoblasts, including the extravillous trophoblasts (EVTs), the villous cytotrophoblast 
(VCTs) and the syncytiotrophoblasts (SCTs) (Figure 11A). No differences in the expression of 
EPS8L1 were observed between the first trimester villi and the placenta tissue at term, except 
for SCTs that showed enriched EPS8L1 expression in SCTs of the first trimester villi as 
compared to the SCTs of the term placenta. To evaluate non-specific staining, the tissue slides 
were stained with antibody diluent without containing the primary EPS8L1 antibody and was 
used as a negative control. To monitor the expression of EPS8L1 during the time course of 




using q-PCR. The analysis showed that the expression of EPS8L1 is consistent throughout 
pregnancy (Figure 11B). 
 
Figure 11. EPS8L1 expression and localization during gestation 
A) Immunohistochemical (IHC) staining of placenta villi of first trimester and placenta tissue at 
term confirmed the trophoblast-specific expression and localization of EPS8L1. The arrows 
show the EPS8L1 expression in different trophoblasts (Extravillous trophoblast (EVT), villous 
cytotrophoblast (VCT) and syncytiotrophoblast (SCT)). B) Quantitative polymerase chain 
reaction (q-PCR) on human placenta tissue (n=141) from early gestation (n=92) and at term 
(n=49) from women with no self-reported medical history, no smoking habit and age >18 were 
analyzed for EPS8L1 mRNA expression. Simple linear regression for expression levels to 
gestational age were not significant from zero (linear regression line and confidence band 
shown, alpha was set at 0.05). 
3.7. EPS8L1 is upregulated in PE but not in IUGR patients 
 
EPS8L1 was found to be significantly upregulated in early-onset PE patients of the Oslo-
cohort-II as compared to the healthy control group. The upregulation was significant both at 
the transcript level (n=28 controls, n=24 early-onset PE and n=22 late-onset PE, *P< 0.05; 
Kruskal–Wallis test; Dunn’s multiple comparisons test) and at the protein level in the early-
onset PE patients (n=4, *P< 0.05, **P< 0.005; Unpaired t-test) (Figure 12A and 12C). To 
determine how prevalent EPS8L1 was dysregulated in PE patients, I analyzed EPS8L1 levels 




Charite and Kiel cohorts confirmed the increased expression of EPS8L1 (*P< 0.05; Kruskal–
Wallis test; Dunn’s multiple comparisons test) in both early-onset (n=14) and late-onset PE 
patients (n=23) compared to their gestational-age matched healthy controls (Control early 
(n=32), control late (n=65) (Figure 12B). In contrast, no significant differences were found in 
the samples derived from IUGR patients of Oslo-cohort-II (n=6), Charite and Kiel cohorts 
(IUGR early (n=28), IUGR late (n=13) as compared to the controls (Figure 12A and 12B), 
suggesting that EPS8L1 dysregulation is specific to PE patients as compared to other 
pregnancy-related disorders, such as, IUGR.  
Notably, EPS8L1 has two protein isoforms (e.g. Isoform A=95 kDa and Isoform B= 66.5 
kDa). The shorter isoform EPS8L1_B was predicted to be a secretary protein. Western blot 
analysis performed on total protein isolated from the placenta tissue of the healthy controls 
(n=4) and early-onset PE patients (n=4) showed that both isoforms were upregulated in early-
onset PE patients (Figure 12C). To confirm that EPS8L1_B is secreted in the human serum, I 
performed western blot analysis (not shown). To validate the upregulation of EPS8L1_B in 
PE patients, I used sera collected from 24th-28th week of gestation from controls and early-
onset PE patients of Manchester cohort for ELISA. A significant upregulation of EPS8L1_B 
expression was found in early-onset PE patients (n=12) as compared to the gestational-age 
matched healthy controls (n=12) (**P< 0.005; Unpaired t-test). As an additional control, sera 
of non-pregnant women (n=6) were included that had low expression of EPS8L1. 
Collectively, the results confirmed that the expression of EPS8L1_B is placental (Figure 12D) 
and suggested that the elevated expression of EPS8L1 in the early-onset PE patients is 
independent of the changes in the gestational-age (Figure 11). EPS8L1 was found to be 
upregulated in PE patients from 4 independent cohorts (Oslo-cohort-II, Charite-cohort, Kiel-
cohort and Manchester-cohort) highlighting the importance of EPS8L1 dysregulation in the 





Figure 12. EPS8L1 is upregulated in early-onset PE but not in IUGR patients 
A) Quantitative-polymerase chain reaction (q-PCR) confirmed the increased EPS8L1 mRNA 
levels in early-onset PE patients (n=24) compared to the healthy controls (n=28) in Oslo-
cohort-II (values are as mean ± SEM, *P< 0.05; Kruskal–Wallis test; Dunn’s multiple 
comparisons test). Late-onset PE (n= 22) also showed increased expression as compared to the 
healthy controls but not significantly (P=0.09; Kruskal–Wallis test; Dunn’s multiple 
comparisons test) B) Quantitative-polymerase chain reaction (q-PCR) performed on samples 
from Charite and Kiel cohort confirmed upregulation of EPS8L1  in early-onset PE (n=14) and 
late-onset PE patients (n=23) compared to gestational-age matched healthy controls (control 
early (n=32), control late (n=65) (values are as mean ± SEM, *P< 0.05; Kruskal–Wallis test; 
Dunn’s multiple comparisons test). No significant differences were found in IUGR patients 
(IUGR early (n=28), IUGR late (n=13) as compared to the healthy controls (Kruskal–Wallis 
test; Dunn’s multiple comparisons test). C) Western blot on placenta tissue of early-onset PE 
patients confirmed upregulation of EPS8L1 isoform A and B at the protein level (n=4, *P< 
0.05, ***P< 0.0005; Unpaired t-test). ImageJ software was used to quantify the protein bands 
of EPS8L1 isoforms from western blot. The quantification data shows the relative amounts as 
ratio of each isoform band relative to the loading control (Actin). D) ELISA confirmed the 
upregulation of EPS8L1 in the serum of early-onset PE patients (n=12) as compared to the 




Unpaired t-test). Serum samples of non-pregnant controls (n=6) were included to confirm that 
expression of EPS8L1 is placental.  
3.8. EPS8L1 expression correlates with the prognostic marker of PE   
 
The pathogenesis of the multifactorial PE is complex and not fully understood.13 It is very 
challenging to detect the disorder early in the pregnancy. Altered circulating levels of anti-
angiogenic (sFlt1; soluble FMS-like tyrosine kinase receptor-1) and pro-angiogenic (PlGF; 
Placental growth factor) factors have been measured in the maternal serum and their ratio 
sFlt1/ PlGF has been used as a prognostic biomarker of PE prognosis.204 To find an 
association between EPS8L1 and an established PE biomarker, the placental expression of 
EPS8L1 was correlated to the sFlt1/ PlGF ratio determined from the maternal serum of the 
same PE patients of the Oslo-cohort-II. The correlation analysis revealed that the placental 
EPS8L1 expression positively correlates and is significant with the sFlt1/ PlGF ratio of the 
early-onset PE patients (Figure 13). 
 
Figure 13. EPS8L1 positive correlation with PE clinical biomarkers 
EPS8L1 placental expression significantly positively correlates to the maternal serum sFlt1/ 
PlGF ratio in early-onset PE patients of the Oslo-Cohort-II as compared to the healthy 
controls (R= 0.5613; *P< 0.0209, Spearman Rank Correlation).  
3.9. EPS8L1 knock-out (KO) in trophoblast cells  
 
EPS8L1 expression was detected in different trophoblast sub-types in the human placental 




of EPS8L1 in BeWo cells by using CRISPR-Cas9 genome editing technology. Both isoforms 
of EPS8L1 were targeted by the specific sgRNA and three constructs were generated to test 
their KO efficiency. The constructs containing sgRNA and Cas9 were transfected in the WT-
BeWo cells and after 48 hours the GFP positive cells were sorted by FACS. The sorted cells 
were cultured as a bulk population and were collected for the EPS8L1 protein analysis after 5-7 
days. The expression of EPS8L1 was analyzed by western blot in the EPS8L1-KO BeWo cells. 
Loss of EPS8L1 expression was detected by the activity of all the sgRNAs when compared 
with the expression in WT-BeWo cells. However, sgRNA2 transfected cells lacked the 
complete loss of EPS8L1 expression (Figure 14). The EPS8L1-KO cells had a very slow 
growth and were unable to survive beyond certain time point (5-7 days). Due to this limitation, 
further analysis on EPS8L1-KO cells were unable to perform. The experiment was repeated at 
least three times with technical replicates but the cells were not able to survive. I also 
performed the EPS8L1-KO in an another trophoblast cell line, SGHPL-4 cells, but the cells 
couldn’t survive after the FACS sorting and were unable to grow as an individual clone. KO 
studies were not informative, therefore, stably overexpressing EPS8L1_SGHPl-4 cells were 
generated as an in-vitro model to mimic the in-vivo condition of PE patients. The functional 
analysis of EPS8L1 are described later in detail. 
 
 
Figure 14. EPS8L1 knock-out (KO) in trophoblast cells 
Western blot confirmed the knock-out of the EPS8L1 in BeWo cells. Three different sgRNA 
(sgRNA1, sgRNA2 and sgRNA3) were transfected and EPS8L1 expression was analyzed in 
each sample as compared to the controls (WT-BeWo cells and cells transfected with construct 







3.10. Characterization of EPS8L1-protein interactors by mass spectrometry (MS)  
 
To understand the potential function of EPS8L1 in human placentation, I performed the mass 
spectrometry analysis to identify the EPS8L1 protein interactors. Since, EPS8L1 was 
identified in both syncytiotrophoblasts (SCTs) and extravillous trophoblast cells (EVTs) of 
the human placental tissue, its interactome was determined in both type of cell lines (BeWo; 
Syncytio-type and SGHPL-4; EVT-type). EPS8L1 (HA-tagged) was transiently over-
expressed in WT-SGHPL-4 and BeWo cells by transfecting the cells with the expression 
plasmid (Figure 15A). As an experimental control, a non HA-tagged EPS8L1 construct was 
used. After 48 hours of transfection EPS8L1 was pulled down by using the HA-tagged beads. 
The mass spectrometry data generated almost 400 proteins individually in each cell line as 
EPS8L1 interactors. A total of 59 proteins came up as significant interactors of EPS8L1 in 
BeWo cells and 115 proteins came as significant interactors in SGHPL-4 cells. (-Log (p-value 
> 1.25) (Table 10A and 10B). As expected, the SGHPL-4 cells and BeWo interactomes were 
different with an overlap of only 17 proteins (bold letters Table 10), suggesting that EPS8L1 
has distinct protein interactors in the two trophoblast cell types. 
To interpret the interactome data, Gene Ontology Enrichment Analysis was performed by 
using the ShinyGO v0.61 software to classify the protein interactors in both cell lines, based 
on their biological function, molecular function and pathways in which EPS8L1 might be 
involved. In addition, KEGG pathway analysis of protein interactors of both cell lines gave an 
overview of the enriched pathways based on the interactors. The analysis showed that a lot of 
interactors are involved in the regulation of translation of proteins in the ribosome, mRNA 
processing and splicing in the spliceosome complex and processing of proteins in the 
endoplasmic reticulum. However, pathways like glycolysis, pentose phosphate pathway, cell 
cell adherent junction that are important for maintaining the cell movement and proliferation 
and IL-17 signaling that is involved in both acute and chronic inflammatory responses and 
activates downstream pathways like NF-kappa B, MAPKs and C/EBPs were found in 
SGHPL-4 cells specifically (Figure 15C). Antigen processing and presentation, endocytosis 
and protein export and also a very important signaling pathway for maintenance of pregnancy, 
Estrogen signaling pathway, was specifically found to be enriched in the interactome data of 
BeWo cells (Figure 15B). Functionally BeWo and SGHPL-4 cells are different trophoblast 
cell lines and the KEGG pathway analysis showed that EPS8L1 interacts with different 




To understand EPS8L1 function, I focused on the top most significant EPS8L1 interactors: 
BAIAP2 and TXNDC5 that were found in both trophoblast cell lines. The functions of these 
two interactors have been studied extensively and could be important to understand the 
function of EPS8L1 in human trophoblasts. BAIAP2 (BAR/IMD Domain Containing Adaptor 
Protein 2 or IRSp53 Insulin Receptor Substrate P53) functions as an adapter protein and 
regulates the actin cytoskeleton remodeling, filopodia formation and cell migration.204  
Knock-out (KO) studies in mice showed its crucial function in cardiac and placental 
development during mice embryo development. Besides this the KO placentas showed 27% 
reduced blood vessels per unit area as compared to the placentas from the healthy mice.205 
This clearly showed that the BAIAP2 has a very important role in the mouse placental 
angiogenesis. TXNDC5 (Thioredoxin Domain Containing 5) is another significant EPS8L1 
interactor and is known to be involved in protein folding, maintaining the cell redox 
homeostasis, metastasis and invasion of cancer cells by controlling the expression of matrix 
metalloproteinases.206  Studies have shown that by repressing TXNDC5 expression, it can 
lead to inhibition of angiogenesis and metastasis. It is expected that EPS8L1 is also mediating 
the similar key biological processes of placenta development by interacting with these 
proteins.   
Some of the other important EPS8L1 interactors and their biological functions (what is known 
in the literature) are summarized in the (Figure 15D). The EPS8L1 MS data gave an insight 
into the possible pathways in which EPS8L1 might be involved in the human trophoblast 
cells. The data showed that EPS8L1 has a functional role in angiogenesis, in maintaining cell 
redox homeostasis, invasion and proliferation of the human trophoblast cells. To further 








Figure 15. EPS8L1-protein interactors in trophoblast cells  
A) EPS8L1 expression construct (HA and non-HA tagged). B) Interactive-plot showing the 
enriched pathways among the EPS8L1-protein interactors found in BeWo cells. C) 
Interactive-plot showing the enriched pathways in EPS8L1-protein interactors found in 
SGHPL-4 cells (Two pathways (nodes) are connected if they share 20% (default) or more 
genes. Darker nodes are more significantly enriched gene sets. Bigger nodes represent larger 
gene sets. Thicker edges represent more overlapped genes). D) Summary of EPS8L1 function 










Table 10. Protein interactors of EPS8L1  











3.11. Functional analysis of EPS8L1 and its contribution to PE pathogenesis 
 
To study the functional role of EPS8L1 in PE development, I established an in-vitro model, 
where to mimic the PE phenotype, EPS8L1 was overexpressed in SGHPL-4 (OE-
EPS8L1_SGHPL-4) trophoblast cells (derived from first trimester human extravillous 
trophoblasts). To stably overexpress human EPS8L1 in SGHPL-4 cells, I used the Sleeping 
Beauty (SB) transposon system (SB100X). The positive clones were selected based on the 
puromycin selection for more than 12 days. In the selected clones, the increased expression of 
EPS8L1 was confirmed at the mRNA and protein levels using q-PCR and Western blotting, 
respectively (Figure 16C and 16D). 
 
 
Figure 16. EPS8L1 overexpression (OE) in trophoblast cells  
A) Sleeping Beauty (SB) transposon system was used to stably overexpress human EPS8L1 in 
SGHPL-4 cells. EPS8L1 overexpressing cells were selected by puromycin selection for more 
than 12 days. B) Immunofluorescence staining showing the endogenous expression of 
EPS8L1 in WT-SGHPL-4 cells and OE-EPS8L1_SGHPL-4 cells. Actin was used as a control. 
C) Overexpression of EPS8L1 was confirmed at mRNA level by quantitative polymerase 




3.11.1. Transcriptome analysis of SGHPL-4 cells overexpressing (OE) EPS8L1 
 
In order to determine the global transcriptome changes generated by the overexpression of 
EPS8L1 in trophoblast cells, RNA-seq was performed on SGHPL-4 cells overexpressing 
EPS8L1. For RNA-seq, total RNA was extracted from both OE-EPS8L1_SGHPL-4 cells and 
WT-SGHPL-4 cells (Control).  
Differential gene expression analysis identified 827 significantly (log2 TPM) dysregulated 
genes in OE-EPS8L1_SGHPL-4 cells as compared to the control cells. Among them 615 
genes and 210 genes were downregulated and upregulated, respectively. The downregulated 
genes were involved in biological processes, such as cell cycle, cell invasion, cell 
proliferation and in placental angiogenesis (Figure 17A and 17B). In contrast, genes involved 
in oxidative phosphorylation were upregulated. To see how closely this in-vitro model mimics 
the EPS8L1 overexpression phenotype in patients, the transcriptome of OE-EPS8L1_SGHPL-
4 cells was compared with the PE patient transcriptome (PMID: 28904069).183 This strategy 
was suitable to identify the global transcriptional changes of the EPS8L1 overexpression 
phenotype of PE (Figure 17C). Notably, EPS8L1 overexpression was significantly 
represented in the PE cohorts compared with the controls (relatively higher in ~ 60% of the 
PE patients and ~25% of the controls, hypergeometric P< 0.03). Genes that were commonly 
differentially expressed (n=230) between the two datasets are shown in the scatterplot (Figure 
17C). In the EPS8L1-overexpressing samples (both in-vitro and in-vivo), PFKFB4, LDHA, 
CKB, PLAC8 and DIO2 were found to be upregulated and JUNB, FOS, C5, CX3CL1, HES4 
and CLDN1 were downregulated as compared to the control (Figure 17C).  
In addition, I used q-PCR on OE-EPS8L1_SGHPL-4 cells to confirm the dysregulation of some 
of the key genes in PE pathogenesis that are involved in the processes like cell invasion and 
cell proliferation. Similar to PE patients, MMP2, MMP3 and MMP9 (cell invasion) and MYC 
(cell proliferation) were found to be significantly downregulated in OE-EPS8L1_SGHPL-4 
cells (Figure 17D). Based on the top dysregulated pathways identified by the transcriptome 
analysis, I further designed the functional assays using the OE-EPS8L1_SGHPL-4 cells as PE 














Figure 17. EPS8L1 overexpression mimics dysregulated pathways in PE 
A) Heat map of differentially expressed genes (DEGs, FDR <0.05) in 3 replicates of OE-
EPS8L1_SGHPL-4 cells vs WT-SGHPL-4 cells (Control) (scaled log2 TPM). DEGs are 
clustered into 7 clusters defining the gene sets involved in particular gene ontology as 
annotated on the plot. Genes in clusters 1, 2, 4, and 6 were downregulated, whereas clusters 3, 
5 and 7 represent the upregulated genes. B) Jittered box-plot represents the pairwise 
comparison of scaled expression (at Log2 scale) of genes in OE-EPS8L1 cells as compared to 
control cells (***P<0.0005; Wilcoxon rank sum test). Every dot represents a single gene 
involved in pathways associated with angiogenesis and invasion. C) EPS8L1 log2 relative 
expression across healthy (blue) and PE (orange) placenta samples (PMID: 28904069) 
subjected to the microarray. PE samples displaying higher expression of EPS8L1 as compared 
to controls. Comparison between the log2 fold change of the differentially expressed genes in 
human PE patient’s vs healthy controls with the genes differentially expressed on EPS8L1 
overexpression in-vitro in SGHPL-4 cells. Hundreds of the genes showed similar differential 
expression patterns; annotated genes are known to be involved in invasion (downregulated) 
and oxidative phosphorylation (upregulated). D) Quantitative polymerase chain reaction (q-
PCR) validated the significant downregulation of MMP2, MMP9 and MYC (n=4, *P<0.05, 
**P<0.005, ****P<0.0005; Unpaired t-test) and upregulation of CCND1 (n=4, *P<0.05; 
Unpaired t-test) in the OE-EPS8L1_SGHPL-4 cells as compared to the control cells. No 
significant differences were found in the expression of MMP3 in OE-EPS8L1_SGHPL-4 cells 
















3.11.2. EPS8L1 overexpression reduces trophoblast cell invasion 
 
The RNA-seq analysis predicted that EPS8L1 overexpression might affect cell invasion (Figure 
17A). To test this hypothesis, transwell invasion assay was designed. The transwell invasion 
assay was performed using control and OE-EPS8L1_SGHPL-4 cells. EGF was used to 
stimulate the invasion of the control and the OE-EPS8L1_SGHPL-4 cells (Figure 18). 
However, even with the EGF treatment, the number of invaded OE-EPS8L1_SGHPL-4 cells 
were significantly reduced (**P<0.005, Unpaired t-test) as compared to the EGF treated 
control cells suggesting that the EPS8L1 overexpression reduced the invasion of the 
trophoblasts. FBS (0%) was used as a negative control. However, no significant differences 
were found in the FBS (0%) treated OE-EPS8L1_SGHPL-4 cells as compared to the FBS (0%) 
treated control cells (n=4, NS=Not Significant; Unpaired t-test). The experiment was performed 
at least three times. 
 
 
Figure 18. EPS8L1 overexpression reduces trophoblast cell invasion 
Transwell invasion assay was performed on control and OE-EPS8L1_SGHPL-4 cells. Images 
(10X) were taken after 12-14 hours of treatment. Fiji-ImageJ software was used to analyze and 
calculate the number of invaded cells. A significantly reduced number of OE-
EPS8L1_SGHPL-4 cells invaded through the matrigel as compared to the control cells with the 
EGF treatment (n=4, **P< 0.005; Unpaired t-test). EGF (10 ng/mL) was applied as a positive 
control to stimulate the invasion and FBS (0%) was used as a negative control. No significant 




FBS (0%) treated control cells (n=4, NS=Not Significant; Unpaired t-test). The experiment was 
repeated at least three times and images were taken from different areas of the well.  
3.11.3. EPS8L1 overexpression affects tube formation  
 
Transcriptome analysis of OE-EPS8L1 cells also showed some genes involved in angiogenesis; 
a key regulatory process for placentation, to be dysregulated. To find out whether 
overexpression of EPS8L1 affects the process of angiogenesis, tube formation assay was 
performed. Using this in-vitro assay, tube characteristics including total number of tubes, tube 
length, loops and branching points between control and OE-EPS8L1_SGHPL-4 cells were 
analyzed. EGF was used to stimulate the tube formation in the cells. FCS (0%) was used as a 
negative control. The assay revealed that the OE-EPS8L1_SGHPL-4 cells exhibited a 
significantly reduced number of tubes, loops and branching points as compared to the control 
cells when treated with EGF (n=6, *P<0.05, **P<0.005; Mann-Whitney test) (Figure 19). The 
results of the experiment show that the overexpression of EPS8L1 affects both the invasiveness 
of the trophoblasts and their ability to form tube-like structures negatively. 
 
Figure 19. EPS8L1 overexpression affects tube-formation 
Tube formation assay performed on control and OE-EPS8L1_SGHPL-4 cells. After 6 hours of 
treatment, cells were analyzed under microscope and images were taken. Wimasis Image 
Analysis software was used to analyze and calculate total tube length, number of tubes, number 
of loops and branching points. In the EGF treated cells, significantly reduced number of tubes, 
loops formation and branching points were detected in OE-EPS8L1_SGHPL-4 cells as 




differences were detected in the total tube length of OE-EPS8L1_SGHPL-4 cells as compared 
to the control cells in EGF treated cells (n=6, NS: Not Significant; Mann-Whitney test). FCS 
(0%) was used as a negative control. No significant differences were found in the total number 
of tubes and length in OE-EPS8L1_SGHPL-4 cells as compared to the control cells treated 
with FCS (0%) (n=6, NS=Not Significant; Mann-Whitney test). However, significantly less 
number of loops and branching points were detected in the FCS (0%) treated OE-
EPS8L1_SGHPL-4 cells as compared to the control cells (n=6, *P<0.05, **P<0.005; Mann-
Whitney test). The data is from six independent experiments. 
3.11.4. EPS8L1 overexpression increases oxidative stress  
 
Transcriptome analysis of OE-EPS8L1_SGHPL-4 cells predicted an altered oxidative 
phosphorylation upon EPS8L1 overexpression. Oxidative stress has been previously associated 
with PE placenta.65 To test that EPS8L1 overexpression might induce oxidative stress, an in-
vitro DCFH-DA assay (2’, 7’- dichlorodihydrofluorescin diacetate) measuring ROS (reactive 
oxygen species) level within the cells was designed. Assay was performed on OE-
EPS8L1_SGHPL-4 cells and was compared to control cells (Figure 20B). In agreement with 
the prediction, the data suggested that overexpression of EPS8L1 induces oxidative stress and 






Figure 20. EPS8L1 overexpression increases oxidative stress  
A) Mechanism of DCFH-DA assay. B) ROS production in control and OE-EPS8L1 SGHPL-4 
cells measured by flow cytometry. Data presented as a mean fluorescent intensity (MFI) of 
the fluorescent signal from the dichlorodihydrofluorescein (DCF) oxidized by ROS. C) ROS 
production in OE-EPS8L1_SGHPL-4 cells detected almost 50% more as compared to the 




















During the course of my PhD project, I accomplished the following targets:  
• Validation of the enriched expression of new set of genes in the human primary 
trophoblasts in the pregnancy-related tissue panel samples as identified by the Illumina 
Body Map and the GTEx consortium. The expression of the candidate genes was not 
detected in the maternal decidua tissue (Figure 8).  
• Confirmation of the enhancer potential of the primate-specific ERV-LTRs (located 
within 10-kb region upstream of the TSS) associated with the trophoblast-specific genes 
(TSGs) by a GFP reporter assay in the trophoblast cell line (Figure 9).  
• Identification of a new set of PE associated genes showing enriched expression in 
trophoblasts mediated by the primate-specific ERV- LTRs (Figure 7).  
• Identification of significant upregulation of a previously uncharacterized gene EPS8L1 
in PE patients, enrichment of expression in human trophoblasts and absence of 
enrichment in the maternal decidua, possibly mediated by a primate-specific ERV-LTR 
(MLT1G1) located approximately 5-kb upstream of the transcription start site (TSS) of 
the EPS8L1 (Figure 9).  
• Confirmation of EPS8L1 expression in the Syncytiotrophoblast (SCTs), the villous 
cytotrophoblasts (VCTs) and the Extravillous trophoblasts (EVTs) of the human 
placenta tissue by analysis of stained human primary villi and the placenta tissue at term 
(Figure 11).  
• Confirmation that EPS8L1 expression is independent of the gestational-age changes and 
has a very low expression level in the non-pregnant females (Figure 11 and 12).  
• Confirmation of upregulation of EPS8L1 in the placenta tissue of PE patients at mRNA 
and protein level in Oslo-cohort-II, at mRNA level in Charite and Kiel cohort and in the 
serum of early-onset PE patients of high-risk pregnancy cohort of Manchester. EPS8L1 
is found to be upregulated in both early-onset and late-onset PE patients but 
predominantly it is found to be upregulated in the early-onset PE patients. An important 
paralog of EPS8L1 is EPS8, however EPS8 was not observed to be dysregulated in PE 
patients of Oslo-cohort-II (Figure 10 and 12).  
• Validation of EPS8L1 isoform_B secretion and detection in the maternal blood. 
EPS8L1 was found to be significantly upregulated already in the 24th week of early-




• Positive correlation of EPS8L1 expression in the placenta tissue with the sFLT1/PLGF 
ratio in the maternal serum of early-onset PE patients, highlighting the importance of 
potential contribution of EPS8L1 in the prognosis of PE (Figure 13).  
• Identification of protein interactions of EPS8L1 in the two trophoblast cell lines (BeWo 
and SGHPL-4 cells). Most of the interactors observed were specific to the two cell 
lines. However, a few common interactors such as BAIAP2 and TXNDC5, known to be 
involved in the placenta development were identified (Figure 15).  
• Demonstration that in-vitro EPS8L1 overexpression model mimics the PE patient 
phenotype. Reduced trophoblast cell invasion, decreased tube formation (angiogenesis) 
and increased oxidative stress were detected in overexpressing EPS8L1 SGHPL-4 cells 
(Figure 18, 19 and 20). Global transcriptome analysis of overexpressing EPS8L1 
SGHPL-4 cells also led to identification of a number of genes dysregulated in the key 
pathways of human trophoblasts and the placenta tissue development (Figure 17).  
Overall, this study lead to a better understanding of the development of the healthy and PE 
placenta. Different set of genes were found to be associated with PE. Moreover, I identified 







4.1. PE- A human-specific disorder 
 
PE is a major cause of maternal and fetal death worldwide.1,2 Approximately 15-20% of all 
preterm births (PTB) and 12-25% of fetal growth restrictions (FGR) are due to PE.41,42 
Various genetic, immunological, endocrine and environmental factors contribute to PE 
pathogenesis.13 The only available treatment of the disorder to date is the removal of the 
placenta tissue and delivery of the infant.4 Curiously, PE has not been observed in animals 
and therefore it is considered to be human-specific.2 Additional studies are required to 
understand the molecular mechanisms of the PE pathogenesis with the focus on understanding 
the question that why is this disorder specific to humans. This study was designed to identify 
certain human-specific aspects of PE. 
Compared to other placental mammals, human placenta and trophoblast cells have multiple 
unique features including morphology, stages of development, mechanism of invasion, 
embryo implantation and mediating physiological exchange between the fetus and the 
mother.207-209 The observed diversity is explained by the rapid evolutionarily changes in the 
mammalian placentation.201 Human placenta so far is the least understood of all human 
organs. Despite its conserved role in supporting the fetal development, it is difficult to model 
human placentation in other mammals. Defects in the placentation result in pregnancy-related 
complications such as PE, which is also poorly characterized so far. In this study, I focused on 
certain human-specific factors of placenta development and their potential contribution to PE 
pathogenesis. 
Human placental evolution had significant assistance from the ancient retroviruses. Human 
endogenous retroviruses (HERVs) are remains of exogenous retroviral infections of the 
primate lineage which occurred approximately 25–40 million years ago.210 The transcription 
of these elements is epigenetically regulated. Although there are no active ERVs in the human 
genome, human ERV-derived sequences can be transcriptionally upregulated upon epigenetic 
changes. Compared to other somatic tissues, the placenta has a unique epigenetic modification 
(e.g. low DNA methylation) that promotes the expression of human ERVs. Human ERVs 
have aggressive transcriptional regulatory sequences, the long terminal repeats (LTRs), that 




domesticated ERV-derived genes (e.g envelope gene) have been incorporated into the 
placentation process and have granted physiological benefit to the host.211,116,148,147 The 
functional evolution of hemochorial placentation in primates as well as the invasive 
phenotype of the human trophoblasts have been associated with ancient retroviral 
infection.124,212, 123 
Certain retroviral (ERV) genes have been co-opted to perform key placental functions such 
as, mediating cell-cell fusions during syncytiotrophoblast differentiation, suppressing 
maternal immunity or protecting the fetus by exogenous viruses.147,213,138 The 
human Syncytin genes, Syncytin 1/HERV-W and Syncytin 2/HERV-FRD, are well-studied 
trophoblast-specific domesticated genes that are derived from the envelope gene of the ERV 
and play a very important role in the human placenta development. Abnormal expression of 
Syncytin-1 has been linked with PE development.134,147,214,9 Surprisingly, rodents have co-
opted retroviral envelope proteins from a distinct retrovirus (ERV) but performing the similar 
role in placenta morphogenesis and physiology, suggesting the independent co-option of the 
retroviral genes during evolution for placental functions in rodents and primates.115 
Importantly, the co-option of unrelated retroviruses (ERVs) in rodents and human placenta 
might have resulted in significant differences (e.g. the invasion process of trophoblasts) 
justifying the diversified placental evolution of mammals. Such differences make it difficult 
to model human trophoblast invasion and pregnancy associated disorders in other species.  
In addition, due to the activity of the endogenous retroviral LTRs (ERV-LTRs), a limited 
number of genes gained unique placenta-specific gene expression in humans. The ERV-LTRs 
are regulatory sequences containing sites for binding of various transcription factors.99,189,215 
Certain ERV-LTRs located nearby to a cellular gene can regulate the expression of the gene 
by acting as an alternative enhancer or promoter. These events are frequent in the human 
placenta. In fact, most of the known proteins whose expression is regulated by the ERV-LTRs 
have an essential role in human placenta development. Notably, their dysregulation have been 
associated with adverse placental morphology and birth outcome.216 
There are various examples of placenta-specific genes driven by human ERV-LTRs such as 
CYP19 in humans. CYP19 is expressed in multiple tissues of the human body driven by 10 
different promoters.156 In human placenta, the expression is mediated by a placenta-specific 
promoter, MER21A, derived from a human ERV-LTR.157 Rodents lack the placenta-specific 
isoform however, similar to humans, bovine and ovine CYP19 have their own placenta-




placental growth and differentiation.217,218,160,161 Moreover, INSL4 (insulin-like peptide 4) is 
the sole member of the insulin-like growth factor gene family that  has a specific expression 
in the human trophoblasts due to the presence of an ERV-derived element in the gene 
promoter. Furthermore, an ERV-LTR, MER11 is known to control the expression of human 
Leptin during pregnancy.131 The absence of MER11 in the murine genome might explain the 
absence of leptin expression in its placenta. In addition, the trophoblast-restricted expression 
of the midline1 (MID1),  human growth factor pleiotrophin (PTN) and endothelin B receptor 
gene (EDNRB) is mediated by an ERV-LTR derived from a HERV-E family that act as an 
alternative placenta-specific promoter/ enhancer containing placenta-specific transcription 
factor binding sites, such as Sp1 site in the ERV-LTR associated with the PTN gene.164,219,220 
Interestingly, these genes exist solely in the humans and Old World monkeys. Among them 
CYP19, INSL4, PTN, and Leptin have been reported previously to be dysregulated in PE 
patients. 176,177,178  179, 180  
Our approach identified already known (Siglec-6, HCG and CRH) but also new candidate 
genes that have unique expression in the human trophoblasts (Table 9).221,222,223,224,225  With 
the help of computational biology tools and by performing wet lab experiments (q-PCR) 16 
candidate genes were shortlisted. Out of the 16 shortlisted genes, 6 genes (e.g. ALDH3B2, 
CYP11A1, SPINT1, DACT2, EPS8L1 and CSF2RB) that were significantly dysregulated in 
the early-onset PE patients of the Oslo-cohort-II were selected for further analysis (Figure 7). 
With the exception of CYP11A1, the rest of the candidate genes were not known to be 
associated with early-onset PE before.196 ALDH3B2, CYP11A1, SPINT1, DACT2, EPS8L1 
and CSF2RB  showed a unique expression in the human trophoblasts and were not detected in 
the maternal decidua except a very low expression of CSF2RB was detected in the human 
pregnancy-related tissue panel (fat, muscle, decidua, placenta tissue, macrophages, 
trophoblast and Hofbauer cells) (Figure 8B). Expression analysis of the 6 candidate genes in 
scRNA-seq data of the human placenta tissue further supported their trophoblast-restricted 
expression (Figure 8C). The results supported the validity of both the working hypothesis and 
the strategy that was used to identify the genes with trophoblast-specific expression and their 
possible contribution in the human placenta development. 
The working hypothesis was based on the previous observations that the ERV-LTRs located 
in the close vicinity upstream (10-kb) of the genes might function as tissue-specific enhancers 
and contribute to the tissue-specific gene expression. ERV-LTRs that have an enriched 




were also identified (Figure 6). Furthermore, their putative activity was predicted by 
analyzing the epigenetic histone modifications and the transcription factor (TF) binding sites 
using publicly available datasets (ChIP-seq) of the human placenta tissue and differentiated 
trophoblasts (Figure 9A). Peaks of histone modifications associated with classical enhancers 
such as enrichment of histone H3 lysine 27 acetylation (H3K27Ac) or histone H3 lysine 4 
monomethylation (H3K4Me1) were detected on almost all of the associated ERV-LTRs. In 
contrast, peaks of repressive (H3K27Me3) chromatin mark were completely absent in the 
region upstream of candidate genes where ERV-LTRs are located (Figure 9A). These 
integrative analyses suggested that these genomic regions are transcriptionally active and 
accessible for the binding of the transcription factors. Binding sites of at least one of the four 
transcription factors GATA2, GATA3, TFAP2A and TFAP2C involved in trophoblast 
differentiation from human embryonic stem cells (ESCs) were found on the identified ERV-
LTRs (Figure 9A).193 High levels of H3K4Me1 (active transcriptional enhancers) together 
with trophoblast-specific transcription factors (TF) binding sites were reliable predictive 
markers of the potential enhancer activity of the associated ERV-LTRs authenticating the 
contribution of the retroviral (ERV) regulatory sequences in cell type specific gene regulation. 
Previously, primate-specific ERV-LTRs such as, MLT1F2 along with MLT1A, MLT1B, 
MER39B and MER21A have been (in-silico) predicted to provide placenta-specific gene 
expression of their neighboring genes.226 It was suggested that in species that lack ERV-LTR-
derived sequences the associated genes had no placenta-specific expression.226  Interestingly, 
our study revealed that MLT1F2 was associated with three different trophoblast-specific 
candidate genes, identified in this study, including CYP11A1, ALDH3B2 and SPINT1 (Figure 
9). Surprisingly, the in-vitro enhancer activity of the three MLT1F2 sequences was different 
in the reporter assay performed in the cultured trophoblast cells (Figure 9C). MLT1F2 
associated with CYP11A1 and ALDH3B2 showed clear enhancer activity, whereas the 
enhancer activity of the MLT1F2, isolated from the upstream region of the SPINT1 gene, was 
not significant as compared to the control (Figure 9C). The different trophoblast-specific 
enhancer activity of the three MLT1F2-derived regulatory regions might be explained by their 
non-identical sequences, potentially providing different transcription regulatory elements. 
These observations highlight the complexity of the mechanisms by which human ERV-LTRs 
have been co-opted to regulate the trophoblast-restricted expression of the nearby genes. 
Trophoblast ChIP-seq analysis and in-vitro enhancer assay revealed the potential role of 




signal could not be precisely mapped on all the human ERV-LTRs since the mapping of the 
reads on the repetitive sequences is rather challenging. Furthermore, in the reporter assay the 
human ERV-LTRs were not in their native chromatin state. Nevertheless, collectively these 
two techniques confirmed our hypothesis about ERV-LTRs and their possible role as 
enhancers. The selected candidate genes associated with these ERV-LTRs were found to be 
dysregulated in the early-onset PE patients of the Oslo-cohort-II. A unifying feature of the 
human ERV-LTR-associated dysregulation of genes in PE is likely epigenetics, however the 
underlying mechanisms are yet to be deciphered. At present, there is no ChIP-seq data 
available on primary human trophoblasts isolated from PE patients, thus the differential 
transcription factor (TF) binding and histone modifications on the ERV-LTRs in PE patients 
correlated to healthy controls could not be analyzed.  
4.2. EPS8L1 in PE pathogenesis  
 
Dysregulated trophoblast-specific genes (TSGs) identified in PE patients which include 
ALDH3B2 (Aldehyde dehydrogenase), CYP11A1 (Steroid hormone production), SPINT1 
(Protease inhibitor), DACT2 (Signaling molecule), CSF2RB (Cytokine receptor) and EPS8L1 
(predicted EPS8-like function) are involved in different cellular processes indicating that 
several pathways might be simultaneously affected in PE. The most dysregulated gene among 
the 6 candidates was CYP11A1 which has been previously associated with early-onset PE 
pathogenesis (Figure 7).196 Nevertheless, this study identified MLT1F2 as potential 
trophoblast-specific enhancer of CYP11A1 providing a mechanistic explanation of its 
enriched expression in the human trophoblasts.  
The human EPS8L1 (EPS8-like-1) was the second most dysregulated gene in the early-onset 
PE patients of the Oslo-cohort-II and currently there are no studies that have been conducted 
to identify the precise role of EPS8L1 in the human trophoblasts or its contribution in PE 
pathogenesis (Figure 12). Therefore, EPS8L1 was chosen further for an in-depth analysis. 
EPS8L1 was identified to be uniquely expressed in the human trophoblasts possibly mediated 
by MLT1G1; a trophoblast-specific enhancer derived from a primate-specific ERV-LTR. 
Elevated levels of EPS8L1 were detected in the human placenta tissue and the serum of early-
onset PE patients from four independent cohorts (Oslo-cohort-II, Charite cohort, Kiel cohort 
and Manchester cohort) (Figure 12). Notably, the dysregulation of EPS8L1 was detected 
specifically in early-onset PE patients and not in other pregnancy-related disorders such as 




candidate for PE studies. Due to its high sequence homology to the human EPS8, it was 
named as EPS8-like 1 and was predicted to function in the epidermal growth factor receptor 
pathway. In addition to EPS8L1, in-silico screening of databases of expressed sequence tags 
(EST) identified further EPS8-like-1 genes that were named as EPS8-Like 2 and 3 (EPS8L2 
and EPS8L3) respectively.227,228 The three EPS8-like proteins share an overall amino acid 
sequence similarity between 27 to 42%, suggesting overlapping functional role among the 
proteins.229  
EPS8 has been known to modulate various signaling pathways; it function as a cytoplasmic 
signaling adapter molecule for receptor and non-receptor tyrosine kinases, including EGFR, 
FGFR, VEGFR and Src kinase.230 Moreover, EPS8 regulates several important biological 
processes such as cell motility, proliferation, apoptosis, cell cycle and cytoskeleton 
remodeling.230 Interestingly, despite its predicted essential cellular function, Eps8 null mice 
were completely healthy and fertile.231 A possible explanation could be the redundancy of the 
functions of the EPS8 family members. Indeed, it was observed that Eps8 KO mice-derived 
fibroblasts were unable to establish membrane ruffles when stimulated with the growth factor 
but could be rescued possibly with Eps8l1.231 Eps8l1 could have restored the RTK-dependent 
cytoskeletal remodeling possibly by establishing a physiological tri-complex with Abi1-and 
Sos-1 that had activated the Rac dependent pathways in Eps8 null mice and rescued the 
phenotype.229,231  
In this study, particularly EPS8L1 but not EPS8 (EGF receptor pathway substrate 8) was 
dysregulated in early-onset PE patients of the Oslo-cohort-II (Figure 10 and 12). EPS8 is 
expressed in numerous tissues in the human body but it was not found among the 335 genes 
that were enriched in the human trophoblasts as compared to the other tissues (liver, lung, 
brain, kidney, heart and placenta). However, EPS8 expression has been detected in a broad 
spectrum of solid tumors including ovarian, lung, breast, thyroid, cervical, pancreatic, 
colorectal carcinoma, brain, pituitary, oral, esophageal and prostate.199,200,201,202,203,232,233,234 
The dysregulation of EPS8L1 in PE patients suggest that these two genes EPS8 and EPS8L1 
might have an independent function especially in the human placenta tissue development. 
The expression of EPS8L1 was detected in both SCTs and EVTs and more than 400 EPS8L1-
protein interactors were identified by mass spectrometry in BeWo (SCT-like) and SGHPL-4 
(EVT-like) cell lines suggesting the possible involvement of EPS8L1 in several biological 




identified in the two types of trophoblast cell lines, suggesting a functional difference of 
EPS8L1 in the two cell types. The trophoblasts associated potential functions of EPS8L1-
protein interactors are summarized in Figure 15D. Among the previously known interactors, 
mass spectrometry analysis identified only ABI1, BAIAP2 and TXNDC5 in the interactome 
of EPS8L1 (Table 10). KEGG pathway analysis of EPS8L1-protein interactors in SGHPL-4 
cells identified metabolic pathways, including glycolysis and pentose phosphate pathway, 
pathways related to cell migration and proliferation by mediating cell-cell adherent junction 
and in inflammatory responses, both acute and chronic, involving IL-17 signaling and 
activating downstream pathways like NF-kappa B, MAPKs and C/EBPs signaling pathways 
(Figure 15C). In contrast, EPS8L1-protein interactors recognized in BeWo cells were 
involved in the estrogen signaling pathway (Figure 15B). Estrogen is a key pregnancy 
hormone; it prepares the uterus during early pregnancy and is involved in the synthesis of 
other pregnancy-related hormones that are essential for sustenance of a healthy pregnancy. 
Besides estrogen signaling, the interactors were found to be involved in antigen processing 
and presentation, endocytosis and protein export from cytoplasm to the exterior of the cell 
(Figure 15B). 
The shared molecular functions in the two cell types included cell adhesion molecule binding 
(HSPA5, HSPA8, PRDX1, BAIAP2), enzyme binding (HSPA9, HNRNPD, P4HB, HSPA5, 
YBX1, HNRNPUL1, HSPA8) misfolded/ unfolded protein binding (HSPA5 HSPA8 HSPA9) 
and mRNA binding (HNRNPA2B1, HNRNPD) cadherin binding (HSPA5, HSPA8, PRDX1, 
RPL15, BAIAP2). BAIAP2/ IRSp53 (BAR/IMD Domain Containing Adaptor Protein 2 or 
Insulin Receptor Substrate P53) has been found to be crucial for mouse embryonic 
development. IRSp53 KO mice embryos were unable to survive due to improper cardiac and 
placental development. IRSp53 was suggested to be important for the proper differentiation of 
the spongiotrophoblast layer in mice.205 IRSp53 has been reported previously as an interactor 
of  Eps8 to establish the IRSp53/Eps8 complex.235 The IRSp53/Eps8 complex then activates 
the Rac signaling that modulates the cell motility and invasion in cancer.235 Based on my MS 
data, I postulated that the interaction of EPS8L1 with BAIAP2/ IRSp53 might also be 
involved in regulating the human trophoblast invasion and placenta tissue development 
(Figure 15D). TXNDC5 (Thioredoxin Domain Containing 5) another EPS8L1-protein 
interactor was identified in both type of trophoblasts, it has been identified previously to 
regulate angiogenesis and metastasis by modulating the expression of SERPINF1 (serpin 




TXNDC5 expression has been reported to significantly reduce the tube-formation 
(angiogenesis).236 The interaction of EPS8L1 with TXNDC5, to mediate the process of 
angiogenesis, might explain the affected tube-like structure formation in OE-EPS8L1 
trophoblast model. PDIA6 (Protein Disulfide Isomerase Family A Member 6) is another 
significant EPS8L1-protein interactor from the family of TXNDC5, reported to function as a 
chaperone and prevent the accumulation of the unfolded proteins inside the cells.237 PDIA6 
has been known to specifically interact with integrin β3 subunit and mediate platelet 
aggregation.206 Other EPS8L1-protein interactors included CBX1 (Chromobox 1) and CBX3 
(Chromobox 3) that are highly conserved non-histone proteins and are known for the 
epigenetic control of the chromatin structure and the gene expression (Figure 15D). Proteins 
involved in maintaining the redox balance, PRDX4 (Peroxiredoxin 4) and PRDX1 
(Peroxiredoxin 1), were also identified as significant EPS8L1 interactors (Figure 15D). Both 
of them have been implicated in physiological and pathological mechanisms involved in 
regulating the cellular response to the oxidative stress.238,239 These processes ultimately affect 
the cell survival and proliferation. The EPS8L1-protein interactors showed that EPS8L1 is 
involved in regulating several different pathways but particularly it has a functional role in 
angiogenesis, maintaining cell-redox homeostasis, invasion and proliferation of the 
trophoblast cells in the human placenta tissue.  
Interestingly, EPS8L1 was found to have a stable expression in the human placenta and is 
independent of the gestational-age changes in the pregnancy (Figure 11A and 11B). Analysis 
of the stained human placenta tissue identified EPS8L1 expression in human trophoblasts of 
the first trimester villi and the term placenta tissue (Figure 11A). Moreover, EPS8L1 
expression analysis of healthy samples from early gestation (n=92) and at term (n=49) 
pregnant females indicated that the expression of EPS8L1 is stable during pregnancy (Figure 
11B). Furthermore, the expression of EPS8L1 was detectable in almost all the trophoblast 
sub-types of the human placenta tissue, including, the extravillous trophoblast (EVTs), the 
syncytiotrophoblasts (SCTs) and the villous cytotrophoblasts (VCTs) as seen in the stained 
human placenta tissue and scRNA-seq analysis (Figure 11A and 8C). Other tissues and cells 
such as fat, muscle, macrophage and Hofbauer cells showed very little or almost negligible 
expression of EPS8L1 and no expression was detected in the maternal decidua, mesenchymal 
stromal cells and blood cells, suggesting that the expression of EPS8L1 is specific to the 
trophoblasts as identified from the scRNA-seq analysis of the human placenta tissue and the 




Intriguingly, EPS8L1 (Isoform-B) was found to be secreted and detected in the maternal 
serum during pregnancy. Western blot analysis performed on the maternal serum identified 
the EPS8L1 secretory isoform B. ELISA performed on the maternal serum from early-onset 
PE women at around 24th- 28th week of gestation, indicated elevated levels of EPS8L1 as 
compared to their gestational age-matched healthy controls. Non-pregnant females, by 
contrast had very low levels of EPS8L1 in their sera, suggesting the importance of EPS8L1 in 
the placenta tissue development during pregnancy (Figure 12D). As all the controls in 
Manchester cohort had a previous history of hypertension, EPS8L1 upregulation was 
specifically detected in the patients who later developed early-onset PE (Figure 12D). 
Moreover, the placental expression of EPS8L1 in early-onset PE patients of Oslo-cohort II 
positively correlated with the clinical ratio of the serum sFLT1/PLGF (clinical biomarker of 
PE) measured in the same PE patients, suggesting the elevated EPS8L1 levels could be used 
for the early prognosis of the PE pathogenesis (Figure 13). 
For the functional studies of EPS8L1 in the trophoblast cells, it was not possible technically to 
perform the EPS8L1-KO in SGHPL-4 cells, since the EPS8L1-KO SGHPL-4 cells were 
unable to grow as an individual clone. However, EPS8L1-KO in BeWo cells was possible and 
cells could survive as an individual clone but died gradually after 5-7 days of in-vitro 
culturing (Figure 14). As a possible explanation, EPS8L1-KO might have disrupted actin 
cytoskeleton remodeling via disrupting the interaction with the ABI that was identified in MS 
data as a specific EPS8L1-protein interactor in BeWo cells and has been implicated 
previously to have a role in the stimulation of the Rac GEF activity to modulate the 
cytoskeletal remodeling.229 Besides this, there could be other reasons as well to understand 
that why the EPS8L1-KO BeWo cells were unable to survive beyond a certain time-point. 
Additional studies are required to understand the possible mechanisms behind the cell death. 
As compared to the KO, EPS8L1 overexpression (OE) studies were more informative. To 
characterize the functional role of EPS8L1 in PE development, EPS8L1 was overexpressed in 
SGHPL-4 (OE-EPS8L1_SGHPL-4) trophoblast cells by using the Sleeping Beauty (SB) 
transposon system (Figure 16).183 Global transcriptome analysis of overexpressing EPS8L1 in 
SGHPL-4 trophoblast cells identified a number of dysregulated genes that are involved in 
various crucial biological pathways related to placenta development such as cell invasion, cell 
proliferation, cell cycle, oxidative phosphorylation and angiogenesis (Figure 17). Following 
the predictions of the high throughput analysis, the transwell invasion assay could confirm the 




18). Even when stimulated with EGF, the number of invaded EPS8L1 overexpressing cells 
were significantly less in comparison to the wild-type (WT) control cells (Figure 18). 
Additionally, q-PCR was performed on OE-EPS8L1_SGHPL-4 cells to confirm the 
dysregulation of some key genes that are involved in cell invasion (e.g. MMP2 and MMP9), 
contributing to PE phenotype. Similar to PE patients, MMP2 and MMP9 were downregulated 
in OE-EPS8L1_SGHPL-4 cells (Figure 17D). The MMP2 and MMP9 (matrix 
metalloproteinases) are essential for vascular and uterine arteries remodeling during 
pregnancy.240,241,242 Invading EVTs abundantly express MMP2 and MMP9 and invade into 
the maternal decidua by degradation of ECM (extracellular matrix proteins).243,244,245,246 
Decreased expression of MMP2 and MMP9 has been reported to affect the process of 
vasodilation and vasoconstriction of the arteries, leading to PE development.247 My data 
suggests, that the overexpression of EPS8L1 affects the expression of MMPs that ultimately 
has a negative impact on the invasion of OE-EPS8L1_SGHPL-4 cells, leading to significantly 
reduced/ shallow trophoblast cell invasion. Decrease in MMP2 and MMP9 results in collagen 
deposition which was shown to affect the normal angiogenesis and spiral arteries remodeling 
during placenta developement.248 In the tube formation assay, the OE-EPS8L1_SGHPL-4 
cells failed to establish tube-like structures, resulting in a significantly reduced number of 
tubes, loops and branching points even after the EGF stimulation (Figure 19). Collectively, 
the dysregulated MMPs, observed in our RNA-seq data could be validated by q-PCR (Figure 
17D) and the predicted affected processes could be confirmed by cell invasion and tube 
formation assays. In addition to MMPs, other genes involved in placental angiogenesis (e.g. 
UNC5B, SCG2, ADM2, COL15A1 and WARS) were found to be significantly reduced in the 
OE-EPS8L1_SGHPl-4 cells (Figure 17B). 
For the healthy placenta tissue development, the trophoblasts undergo rapid proliferation and 
invasion by expressing significantly higher levels of certain proto-oncogenes such as c-
MYC.249 Similar to previous PE patient reports, significantly reduced levels of c-MYC were 
detected in the OE-EPS8L1_ SGHPl-4  cells (Figure 17D). Therefore, leading to the 
decreased trophoblast differentiation, proliferation and invasion as indicated from the data (q-
PCR and invasion assay).250,251,252 The expression of certain other genes involved in the 
regulation of cell proliferation (e.g. TP73, DLL1, CDH3, CCND2, BCL2, EGR1 and EGR3) 
were also found to be reduced in the EPS8L1-OE_SGHPL-4 cells (Figure 17A). Furthermore, 
the oxidative stress was also found to be significantly elevated in OE-EPS8L1_SGHPL-4 cells 




elevated oxidative stress in PE is not known. However, it has been hypothesized that the 
abnormal trophoblast invasion, resulting in insufficient placental perfusion and ischemia 
induces oxidative stress that can contribute in the pathogenesis of PE.253,254 Reactive oxidative 
species (ROS) have been reported to regulate the transcription of genes and pathways that 
might have an effect on the trophoblast proliferation, invasion and angiogenesis.255 
Trophoblast invasion, proliferation, angiogenesis and oxidative stress are linked biological 
processes that are crucial for the human placenta development during pregnancy. The data 
suggests that the overexpression of EPS8L1 might contribute to PE development by affecting 
all of the above discussed pathways.  
To understand how closely OE-EPS8L1_SGHPl-4 cells, an in-vitro PE-model, mimics the 
transcriptome of PE patients, the data of OE-EPS8L1_SGHPL-4 cells was intersected with the 
PE patient’s microarray data set of 24 PE patients and 22 healthy control samples (Figure 
17C). Importantly, in the OE-EPS8L1_SGHPl-4 cells and patients, around 230 genes were 
commonly differentially expressed, suggesting that the in-vitro EPS8L1 overexpressing model 
can faithfully capture some of the features of PE and highlight the significance of 
upregulation of EPS8L1 in PE pathogenesis. In the overlapping processes with PE patients, 
genes involved in oxidative phosphorylation (PFKFB4, LDHA, CKB, PLAC8 and DIO2) and 
cell-invasion (JUNB, FOS, C5, CX3CL1, HES4 and CLDN1) were identified (Figure 17C). 
Taken together, the data showed that the upregulation of EPS8L1 in PE has an effect on the 
pathways related to trophoblast invasion and proliferation, angiogenesis and oxidative stress 
(Figure 18, 19 and 20). All of the above mentioned pathways have been reported to be 
dysregulated in PE patients. 
4.3. ERV-LTRs and dysregulated trophoblast-specific gene (TSG) expression in PE 
 
Another important question is what causes the dysregulation of the ERV-LTR-driven genes in 
PE? It has been hypothesized that disturbed epigenetics in PE can affect the ERV-LTRs and 
thus the expression of the ERV-LTR-regulated genes. Therefore, I investigated the effects of 
disturbed epigenetics on ERV-LTR-associated trophoblast-specific gene expression in PE 
patients and in healthy controls. I specifically analyzed the CpG methylation sites of the 
ERV-LTRs in the healthy controls and PE patients by treating the placental genomic DNA 
with sodium bisulphite. Bisulphite treatment (unmethylated C to T conversion) made it 
difficult to amplify ERV-LTR sequences which are highly repetitive sequences. Due to this 
technical limitation, I could successfully amplify only one ERV-LTR, MLT1F2-2, associated 




results of MLT1F2-2 from healthy (n=3) and early-onset PE patients (n=3) revealed that the 
CpG site in early-onset PE patients is unmethylated in all of the 3 PE patients tested, whereas 
it is methylated in the healthy control (not shown). Demethylation of the CpG site in 
MLT1F2-2 of PE patients could be one of the factors to augment CYP11A1 expression in the 
early-onset PE patients. However, more studies are required to support these results and the 
hypothesis of global epigenetic deregulation, resulting in the ERV-LTR-derived 
transcriptional dysregulation in PE patients.  
Currently, the specificity and novelty of the human trophoblasts has widely been studied, but 
still there are many unanswered questions. The complexity of the human placentation makes 
it very challenging and difficult to study. However, recent technologies such as single-cell 
RNA-seq, organoid cultures and genetic engineering techniques such as CRISPR has made it 
easier to better understand the normal human placenta development. More appropriate 
knowledge of the human placenta development during pregnancy will eventually enhance the 
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6.  Supplementary information 
 
Figure 21. Characterization of single cell RNA-seq data of human placenta tissue 
Graphical representation of identified trophoblast sub-type clusters from 8th and 24th week of 
gestation (PMID: 30042384; GEO accession: GSE89497) as shown in the UMAP plot (left 
side of the figure). The cell type for each cluster was identified according to the known 
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